

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Navigator Program for Hospitalized Adults Experiencing Homelessness: Study Protocol for a Pragmatic Randomized Controlled Trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-065688
Article Type:	Protocol
Date Submitted by the Author:	20-Jun-2022
Complete List of Authors:	Liu, Michael; Harvard Medical School; MAP Centre for Urban Health Solutions Pridham, Katherine; MAP Centre for Urban Health Solutions Jenkinson, Jesse; Unity Health Toronto, MAP Centre for Urban Health Solutions Nisenbaum , Rosane ; St Michael's Hospital, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute; University of Toronto Dalla Lana School of Public Health Pedersen, Cheryl; MAP Centre for Urban Health Solutions Brown, Rebecca; MAP Centre for Urban Health Solutions Uirani, Sareeha; MAP Centre for Urban Health Solutions Ellerington, Fred; St Michael's Hospital Ranieri, Alyssa; St Michael's Hospital Dada, Oluwagbenga; MAP Centre for Urban Health Solutions To, Matthew; University of Toronto Fabreau, Gabriel; University of Calgary , Medicine McBrien, Kerry; University of Calgary Cumming School of Medicine, Family Medicine Stergiopoulos, Vicky; Centre for Addiction and Mental Health Palepu , Anita; The University of British Columbia Hwang, Stephen.; St Michael's Hospital Centre for Urban Health Solutions, MAP Centre; St Michael's Hospital
Keywords:	GENERAL MEDICINE (see Internal Medicine), Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH

SCHOLARONE[™] Manuscripts

Page 1 of 31	BMJ Open
1	
2 3 4 5	Navigator Program for Hospitalized Adults Experiencing Homelessness Study Protocol for a Pragmatic Randomized Controlled Trial
6 7	Michael Liu, MPhil ^{1,2} , Katherine Francombe Pridham, MSW ¹ , Jesse Jenkinson, PhD ¹ , Rosane
8	Nisenbaum, PhD ^{1,3} , Cheryl Pedersen, MSc ¹ , Rebecca Brown, BA ¹ , Sareeha Virani, BSc ¹ , Fred
9 10	Ellerington, BA ⁴ , Alyssa Ranieri, MSW ⁴ , Oluwagbenga Dada, MSc ¹ , Matthew J. To, MD ^{1,5} ,
11 12	Gabriel E. Fabreau, MD, MPH ^{6,7} , Kerry A, McBrien, MD, MPH ^{6,8} , Vicky Stergiopoulos, MD,
13 14	MHSc ^{9,10} , Anita Palepu, MD, MPH ^{11,12} , Stephen W. Hwang, MD, MPH ^{1,4}
16 17	¹ MAP Centre for Urban Health Solutions, Unity Health Toronto, Ontario, Canada
18 19 20	² Harvard Medical School, Boston, Massachusetts, United States of America
21 22 23	³ Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Ontario, Canada
24 25 26	⁴ Division of General Internal Medicine, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada
28 29	⁵ Division of Family and Community Medicine, University of Toronto, Ontario, Canada
30 31 32	⁶ Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Canada
33 34 35 26	⁷ Department of Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada
37 38 39	⁸ Department of Family Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada
40 41 42	⁹ Centre for Addiction and Mental Health, Ontario, Canada
42 43 44	¹⁰ Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada
45 46 47	¹¹ Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, British Columbia, Canada
48 49 50 51 52 53	¹² School of Population and Public Health, University of British Columbia, British Columbia, Canada
54 55 56 57 58 59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Corresponding Author:

Stephen W. Hwang, MD, MPH MAP Centre for Urban Health Solutions Unity Health Toronto Toronto, Ontario, Canada <u>Stephen.Hwang@unityhealth.to</u>

Word Count: 4000 (Main Text), 295 (Abstract)

Keywords:

Homeless Persons; Health Services; Randomized Controlled Trial; Hospitalizations; Readmissions; Transitions of Care

or oper terror on the one

BMJ Open

Abstract

Introduction: People experiencing homelessness suffer from poor outcomes after hospitalizations due to systemic barriers to care, suboptimal transitions of care, and intersecting health and social burdens. Case management programs have been shown to improve housing stability, but their effects on broad post-hospital outcomes in this population have not been rigorously evaluated. The Navigator Program is a Critical Time Intervention case management program that was developed to help homeless patients with their post-discharge needs and to link them with community-based health and social services. This randomized controlled trial examines the impact of the Navigator Program on post-hospital outcomes among adults experiencing homelessness.

Methods and Analysis: This is a pragmatic randomized controlled trial testing the effectiveness of the Navigator Program at an urban academic teaching hospital and an urban community teaching hospital in Toronto, Canada. Six hundred and forty adults experiencing homelessness who are admitted to the hospital will be randomized to receive support from a Homeless Outreach Counsellor for 90 days after hospital discharge or to usual care. The primary outcome is follow-up with a primary care provider (physician or nurse practitioner) within 14 days of hospital discharge. Secondary outcomes include post-discharge mortality or readmission, number of days in hospital, number of emergency department visits, self-reported care transition quality, and difficulties meeting subsistence needs. Quantitative outcomes are being collected over a 180day period through linked patient-reported and administrative health data. A parallel mixedmethods process evaluation will be conducted to explore intervention context, implementation, and mechanisms of impact.

Ethics and Dissemination: Ethics approval was obtained from the Unity Health Toronto Research Ethics Board. Results of the main trial and process evaluation will be reported in peerreviewed journals and shared with hospital leadership, community partners, and policy makers.

Trial Registration: This trial has been registered with ClinicalTrials.gov (NCT04961762)

Strengths and Limitations of the Study

- The Navigator Program is a patient-centered case management intervention informed by a prior prospective cohort study and designed in tandem with community partners, healthcare teams, and people with lived experience of homelessness.
- Linkage of patient-reported data with administrative health data allows for rigorous assessment of a much wider range of post-hospital outcomes relative to previous case management studies for people experiencing homelessness.
- This randomized controlled trial is accompanied by a parallel mixed-methods process evaluation that will investigate intervention implementation, causal mechanisms, study context, participant experiences, and outcomes.
- Blinding of participants, homeless outreach counselors, and healthcare teams are not possible given the active and collaborative nature of the intervention.
- This study takes place at an urban academic teaching hospital and an urban community teaching hospital in Toronto, Canada, and findings may not be generalizable to individuals experiencing homelessness in other contexts and settings.

BMJ Open

Introduction

Background and Rationale

More than 235,000 Canadians experience homelessness annually, of which 27% are women, 19% are youth, and a growing number are identifying as racial, ethnic, sexual, and gender minorities.^{1,2} This population experiences disproportionate intersecting physical, mental, and social burdens that greatly increase morbidity and mortality relative to the general population.^{3–5} For example, rates of acute and chronic physical health problems, trauma, mental illness, and substance use are much higher among homeless adults.^{6–8}

Homeless individuals often experience substantial barriers to obtaining health care and frequently suffer from unmet health needs.^{9–11} Many have other immediate competing priorities such as securing food and shelter that preclude consistent engagement with healthcare services.^{12,13} Homeless individuals are also much less likely to have a primary care provider (PCP) or usual source of care compared to the general population.^{14,15} Lack of primary care likely contributes to poor outcomes among the homeless population, given that access to primary care is associated with lower mortality and reductions in unnecessary emergency department (ED) visits and hospital admissions.^{16,17} Indeed, there is abundant evidence suggesting that homeless adults rely heavily on acute care services, and rates of ED visits and hospitalizations are much higher among homeless versus non-homeless adults.^{18–21} A related problem is the high rate of hospital readmissions among homeless adults.^{19,20,22,23} Many of these readmissions are thought to be potentially preventable with more complete treatment and better coordination of health and social services following hospital discharge.^{24,25} In the general population, timely access to primary care follow-up after hospitalization has been consistently associated with lower rates of readmissions.^{26–28} Qualitative studies have also revealed that homeless individuals face unique challenges following discharge from hospital, such as difficulties storing medication, inability to find shelter, and not being provided appropriate discharge instructions.^{29–31} Altogether, systemic barriers to primary care, competing priorities, and poor care transitions all contribute toward poor post-hospital outcomes and reliance on acute care settings among homeless individuals.

BMJ Open

Case management is a core component of care for homeless individuals, serving to navigate and coordinate health and social services for this population.³² Such programs have been adapted and implemented for several subgroups of homeless individuals, including frequent users of acute healthcare services and those with complex needs and mental illness.^{33–35} Systematic reviews have found that case management is effective in improving housing stability, reducing substance use, and removing barriers to securing employment in this population.^{32,36} However, few studies have rigorously evaluated the effect of case management on broad post-hospital outcomes among the overall homeless population. One randomized controlled trial (RCT) of a combined transitional housing, long-term housing, and case management intervention reported reductions in hospitalizations, number of hospital days, and ED visits among homeless adults with chronic illnesses.³⁵ However, this study could not evaluate the independent effects of the multiple intervention components and did not assess other post-hospital or patient-reported outcomes. A smaller RCT of a Critical Time Intervention (CTI) case management program focused specifically on homeless patients with severe mental illness was found to improve continuity of care, prevent homelessness, and reduce psychiatric readmissions following hospital discharge.37-39

Accordingly, this current RCT seeks to investigate the effectiveness of an adapted CTI case management program – the Navigator Program – in improving post-hospital outcomes among adults experiencing homelessness at an urban academic teaching hospital and an urban community teaching hospital in Toronto, Canada. CTI is a time-limited case management program which delivers focused case management at critical times or situations in the lives of clients, such as transitioning from hospital care to community care.³⁶ The Navigator Program features Homeless Outreach Counsellors (HOCs) – whose roles are to create strong links between community services and patients through regular contact, supporting patients in following their post-discharge care plans, and helping patients in meeting their health- and social-related competing priorities. This intervention was informed by a recent prospective cohort study conducted at the same hospital, which found that having an active case manager, sending discharge summaries to PCPs, and informal support were associated with reduced readmissions among homeless adults.²² The first HOC position was created in February 2019 and has since been expanded to two positions and adapted through conversations with community

BMJ Open

partners and hospital staff. Ultimately, the goal of the Navigator Program is to help homeless patients who are discharged from the hospital overcome systemic barriers and discontinuities in care that often result in poor health and high acute care utilization.

Objectives

This RCT seeks to evaluate the effectiveness of the Navigator Program in improving posthospital outcomes among adults experiencing homelessness. It will specifically evaluate outcomes related to PCP follow-up, acute care utilization, difficulties meeting subsistence needs, care transition, and overall health following hospital discharge.

A detailed mixed-methods process evaluation will be conducted alongside the RCT. This evaluation primarily aims to provide a deeper understanding of intervention implementation, mechanisms of change within the intervention, and the way in which the Navigator Program interacts with the internal and external contexts to influence both implementation and RCT outcomes in expected or unexpected ways.^{40,41} This evaluation will also aim to understand the inhospital and post-discharge experiences of participants in the intervention and control arms, exploring differences and similarities qualitatively. It is important to investigate how RCT outcomes are shaped by intervention implementation or by the intervention itself, and to identify which parts of the Navigator Program did or did not work to achieve the intended goals and why.

Methods and Analysis

Design and Setting

This study is a pragmatic RCT that is being conducted at an urban academic teaching hospital (St. Michael's Hospital) and an urban community teaching hospital (St. Joseph's Health Centre) in Toronto, Canada. Recruitment began in October 2021 and is ongoing.

Eligibility Criteria

To be eligible for the study, patients must meet the following criteria: (1) are 18 years of age or older, (2) be admitted to any medical or surgical service (excluding psychiatry and obstetrics), and (3) are identified as experiencing homelessness (as per the Canadian definition of homelessness) at the time of admission or anytime during the hospital admission.⁴² Patients will

BMJ Open

be excluded from the study if they meet any of the following criteria: (1) are unable to provide informed consent or (2) were connected with a HOC prior to the initiation of the RCT and have received services from the HOC within 90 days preceding their current admission. Each individual patient can be randomized only once during the study period. Patients admitted to psychiatric and obstetric services are excluded from this study because optimal immediate postdischarge follow-up for these patients should be with specialists rather than with PCPs.^{43,44} Furthermore, recommended follow-up timeframes for these patients are often longer than 14 days, thus rendering the primary outcome not applicable.

Recruitment and Data Collection

Clinical or research staff will identify potential participants on weekdays. Once identified, a member of the patient's circle of care will ask the patient for permission to introduce the patient to the research team. The research team will then confirm patient eligibility and explain the purpose, process, risks, and benefits of the study to potential participants. Participants may choose to enroll in the study by providing written informed consent.

A baseline interview will be conducted with participants prior to randomization and as a soon as possible after admission to the hospital and confirmation of eligibility. Sociodemographic information will be collected, including age, gender, race, Indigenous identity, education level, housing status, and social service utilization. Participants who complete the baseline interview will receive a \$20 CAD gift card to compensate them for their time. Another 30-day interview will take place at least 30 days (but no longer than 50 days) after the discharge date to assess patient-reported post-hospital outcomes. At this time, the research team will contact PCPs to ascertain any follow-up visits. Baseline and 30-day interviews will be conducted in person or remotely. Data from interviews will be collected with tablets using electronic surveys hosted by Snap Professional Software.

The research team will also undertake a chart review of hospital records after discharge to ascertain characteristics of the admission, information about discharge, participant health information, and history of alcohol and substance use.

BMJ Open

Plans to Promote Continued Participation

Several strategies will be implemented to minimize attrition. At the baseline interview, study participants will be asked to provide detailed contact information, as well as the names and contact information of family, friends, and other service providers who may be contacted if the research team cannot reach the participant directly. In addition to active outreach from the research team, participants will be instructed to contact the research team after discharge to schedule a 30-day interview. Participants who contact the research team 2-3 weeks following their discharge to confirm their contact information and schedule the 30-day interview will receive an additional \$10 CAD honorarium upon completion of the interview. Participants who complete the 30-day interview will also receive a \$40 CAD honorarium and reimbursement for any travel-related expenses, when applicable, for the interview.

Randomization

Participants will be randomized by a third-party internet randomization service (<u>randomize.net</u>). The program will assign participants to either the intervention or the usual care arm using permuted-block randomization, with a 1:1 allocation ratio and random permuted blocks. This process will maintain balanced group sizes between the intervention and usual care arms at intermediate points in the recruitment process and minimize the possibility of the research team predicting study allocation.⁴⁵

Intervention

Participants randomized to the intervention arm will be assigned to work with an HOC. The HOC will connect with participants as early as possible during the admission and will provide support for 90 days after hospital discharge. The period of support may occasionally be extended beyond 90 days for certain patients, if the HOC deems this to be necessary and appropriate. The main role of the HOC is to support continuity and comprehensiveness of care by helping participants follow their post-discharge plans and facilitating strong links with community-based health and social services. Day-to-day HOC activities fall into five main categories: 1) making connections and referrals to community-based providers, 2) supporting and advocating for patients during the hospital stay and discharge process, 3) supporting patients with health-related matters during the post-discharge period, 4) supporting patients with social-related matters

during the post-discharge period, and 5) transferring patient-related information to other healthcare and community-based providers **(Table 1)**. The intensity and types of support from HOCs will be tailored to the specific needs of the individual.

Usual Care

Participants in the usual care arm will be discharged without support from the HOCs. However, all participants will still receive support as usual from Care Transition Facilitators (CTFs) and/or social workers. CTFs and social workers help patients during their hospital stay to arrange discharge plans and make follow-up arrangements. However, unlike HOCs, CTFs and social workers do not typically work with patients after hospital discharge.

The typical discharge process involves counseling from the discharging physician and healthcare team, who make recommendations or appointments for follow-up care as needed. Patients will also be provided with a written discharge summary and prescription(s) as needed. If the patient has an identified PCP, a copy of the discharge summary is emailed to the PCP.

Data Linkage

ICES is an independent, non-profit research institute funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. As a prescribed entity under Ontario's privacy legislation, ICES is authorized to collect and use health-related data for the purposes of health system analysis, evaluation, and decision support. Secure access to these data is governed by policies and procedures that are approved by the Information and Privacy Commissioner of Ontario.

Data from participants covered under the publicly-funded single-payer Ontario Health Insurance Plan (OHIP) will be linked to ICES administrative health data from 3 years prior to the admission to 1 year following discharge.⁴⁶ PCP visits, outpatient visits, ED visits, inpatient hospitalizations, and mortality will be ascertained from the OHIP physician billing claims database, the National Ambulatory Reporting System, the Discharge Abstract Database, the Ontario Mental Health Reporting System, and the Registered Persons Database.

	Category	Examples
1.	Connection to Community-Based Providers	Referral to case managers, housing workers, harm reduction services, and shelt
2.	Patient Advocacy During Hospital Stay and Discharge Process	 Link to addiction and harm reduction services within hospital and surrounding area Help patients apply for housing, social benefits, and identification Connect to social activities and provide other materials for in-hospital entertainment Participate in creation of discharge plan and support patient/team in the actual discharge process
3.	Health-Related Support After Discharge	 Remind patients about their medication regimes Arrange medication storage at post-discharge setting Help patients fill prescriptions (direct patients or accompany them to local pharmacies) Help patients with accessing opioid agonist therapy and safer supply Help patients procure medical aides and devices Remind patients about upcoming medical appointments Attend medical appointments with patients Help patients find and connect with primary care providers Help patients arrange for home care, wound care, eye care, and dental care Connect patients to disease-specific programs Purchase medical-related items to help follow through with post-discharge pla
4.	Social-Related Support After Discharge	 Help patients apply for housing, social benefits, and identification Arrange transportation to post-discharge setting Help patients find alternative shelter based on unique needs
5.	Information Transfer	 Follow-up with shelters and case managers to ensure that they have the patient discharge plan and are supporting it Ensure that outpatient services are also aware of patient discharge plan and following through with it Ensure that this hospital and other hospitals are aware of the hospitalization and discharge plan

Outcomes

The primary outcome is follow-up with a PCP (physician or nurse practitioner) within 14 days of hospital discharge. This outcome was chosen given the unique and substantial barriers to primary care access faced by the homeless population and the fact that timely access to primary care after hospitalization is linked to better outcomes.^{15,47} In-person visits, virtual encounters, and phone calls will all be considered as follow-up with a PCP. The primary outcome will be ascertained through participant self-report at the 30-day interview, phone calls to PCP offices, and ICES data linkage. In the event of discrepancies between these sources of information, we will use prespecified rules to adjudicate the primary outcome (**Appendix Table 1**).

Several other outcomes will be assessed given the multiple potential effects that are expected from this complex intervention.⁴¹ Secondary outcomes include a composite measure of all-cause mortality or readmission, total number of days spent in hospital post-discharge, and number of ED visits within 30-, 90-, and 180-days post-discharge. Acute care utilization (readmissions and days in hospital) outcomes will not include labor and delivery visits and planned readmissions. If a patient is transferred between services within the hospital, the entire hospital stay will be treated as a single admission. Other secondary outcomes include self-reported quality of care transition (three-item Care Transitions Measure) after hospital discharge and self-reported change in difficulties meeting subsistence needs (RAND Course of Homelessness Scale) at the time of the 30-day interview relative to baseline.^{12,48} Exploratory outcomes include change in health status (EQ-5D-3L) at the time of the 30-day interview relative to baseline, change in quality of life (EQ-5D Visual Analogue Scale) at the time of the 30-day interview relative to baseline, leaving against medical advice at discharge, medication adherence (eight-item Morisky Medication Adherence Scale) at the time of the 30-day interview, connection to a case manager in the community at the time of the 30-day interview, attendance of any non-PCP healthcare appointment within 180-days post-discharge, and time to all-cause mortality or readmission after discharge.^{49,50} Only non-PCP appointments made by the time of discharge and documented in the discharge summary will be assessed for attendance. Only participants that did not previously report contact with a case manager in the 30-days prior to the baseline interview will be eligible for the connection to a case manager outcome. A summary of outcome domains and study

BMJ Open

instruments is provided in **Table 2** and detailed descriptions of study instruments are provided in **Appendix Table 2**.

Sample Size

No previous data are available to ascertain 14-day PCP follow-up rates after hospitalization among people experiencing homelessness under usual care. However, a previous study reported that 14-day PCP follow-up rates after hospitalization among low socioeconomic status (SES) patients was ~48%.⁵¹ An assumption was made that 14-day PCP follow-up rates after hospitalization among people experiencing homelessness under usual care is around 2/3 that of low-SES patients (32%). This study is powered to detect an effect size of 12%, equivalent to a 37.5% increase in relative rate of follow-up with a PCP within 14 days of discharge. With an α of 0.05, 256 participants per study arm will result in an 80% power to test the study hypothesis. Given an estimated 20% attrition rate based on past studies in this population,⁵² a total of 640 participants will be recruited for this study.

Blinding

It will not be possible to blind participants, HOCs, or healthcare teams given the active and collaborative nature of the intervention. However, data collectors and data analysts will be blinded to the allocation of participants. The research team member who performs study allocation for a participant will not be involved in the 30-day follow-up interview for that participant.

Statistical Analyses

All analyses will follow the intention-to-treat principle. Sample characteristics will be summarized by descriptive statistics (mean, standard deviation, median, interquartile range, and proportion). We will also construct graphs to explore relationships and estimate correlations between participant characteristics and outcomes. Descriptive comparisons between group baseline characteristics and outcomes will be performed with χ^2 or Fisher exact tests for categorical variables and with t-tests or Wilcoxon rank sum tests for continuous or count variables.

Domain	Variables	Instruments
Patient-Reported Outcomes	- Health Status ^{a,b}	- EO-5D-3L
ratione responded Outcomes	Quality of Lifeab	EQ 5D Visual Analogue
		- EQ-5D Visual Allalogue
	- Medication Adherence ⁶	Scale (VAS)
	- Care Transition Experience ^b	- Morisky Medication
	- Difficulties meeting subsistence needs ^{a,b}	Adherence Scale 8-item
		(MMAS-8)
		- Care Transitions Measure
		3-item (CTM-3)
		- RAND Course of
		Homelessness Scale
Healthcare Utilization	Follow-up with primary care provider ^{b.d}	
	Hospital readmissions with in 20 days 00	-
	- Hospital feadmissions within 30-days, 90-	
	days, and 180-days post-discharge ^{0,d}	
	- Emergency department visits within 30-	
	days, 90-days, and 180-days post-	
	discharge ^{b,d}	
	- Number of days spent in hospital within 30-	
	days, 90-days, and 180-days post-	
	discharge ^{b,d}	
	- Leaving against medical advice ^c	
Social Sarvice Utilization	Connection to case manager	
Martalia d	- Connection to case manager	-
Mortality ^u	O,	-
^a Self-reported from b	aseline interview	
^b Self-reported from 3	0-day interview	
Collocted from disch	arga chart raviaw	
	arge chart review	
^d Ascertained from ad	ministrative health data	
		1 /
		1/1

BMJ Open

The primary analysis will be performed using the χ^2 test to compare two independent proportions of 14-day PCP follow-up. The difference in proportions (risk difference, RD) and 95% confidence interval (CI) will be estimated using the Wald method.⁵³ Two secondary analyses will be conducted. The first is a log-binomial regression model including the intervention arm indicator as the covariate. The risk ratio and 95% CI will be estimated from the model. The second is a logistic regression model including the intervention arm indicator as the covariate. The odds ratio (OR) and 95% CI will be estimated from the model. To explore potential subgroup effects, multivariable logistic regression models for the primary outcome will be constructed including each of the following pre-specified covariates, one-at-a-time and with corresponding interaction terms with the intervention arm: age, sex, current illicit drug use, current risky alcohol use, Charlson comorbidity index score, and prior acute care utilization for a mental health reason.

For secondary and exploratory binary outcomes, logistic regression models will be used to estimate ORs and 95% CIs. For count outcomes, Poisson or negative binomial regression models (if over-dispersion is suggested by the data) will be used to estimate rate ratios and 95% CIs. For cross-sectional continuous outcomes, linear regression models will be constructed. For longitudinal continuous outcomes, we will consider linear mixed models or generalized estimating equations, depending on the outcome distribution. Models will include the intervention arm indicator, time (baseline versus 30-day interview), and the interaction of intervention arm by time. A significant interaction will indicate that the change from baseline is different between the study groups. This difference and 95% CI will be estimated. For time to all-cause mortality or readmission after discharge, a survival analysis will be performed. Cumulative event rates will be calculated with the Kaplan-Meier method, with event or censoring times calculated from the date of discharge. Differences in Kaplan-Meier survival curves between the study arms will be assessed using the log-rank test.

Any missing data will be considered, and multiple imputation will be performed if indicated either for the main analyses or as sensitivity analyses.⁵⁴ All analyses will be conducted using R, STATA, and SAS. All statistical tests will be two-sided and a p-value of 0.05 or less will indicate statistical significance. Adjustments will not be conducted for multiple comparisons.

This protocol follows guidance from the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT).⁵⁵

Process Evaluation Methods and Analysis

In keeping with recommendations from the Medical Research Council on Process Evaluations of Complex Interventions,⁴⁰ we have designed a pragmatic mixed-methods process evaluation that will gather quantitative measures on program activities and qualitative data on how participants experience the intervention and how staff experience its implementation and operationalization. Three domains will be explored in this evaluation: implementation, mechanisms of impact, and context. Multiple data collection methods will be employed to better understand intervention implementation, mechanisms of change, and important contextual influences on the Navigator Program. These methods and their corresponding process evaluation domains, research questions, and data sources are outlined in **Table 3**, and include chart review, non-participant observation (NPO), semi-structured interviews, and field notes. Chart review will include data on the number and nature of interactions between HOCs and participants, community service providers, and healthcare team, collected from a database developed specifically for the Navigator Program. NPO is a process of observing participants and the program setting without actively participating, and can be helpful for assessing the finer details and spirit of implementation, mechanisms of change and program activities, and contexts.⁵⁶ In this study, NPO will entail accompanying the HOCs as they do their day-to-day work at the hospital and in the community. Semi-structured interviews will be conducted with the HOCs (n=2), the implementation team (n=4), hospital physicians and staff (n=25-50), community service providers (n=10-20) that interact with the Navigator Program, and individuals experiencing homelessness enrolled in the study in both the intervention (n=15-25) and control arms (n=15-25).

Process Evaluation Domains	Research Questions	Core Information	Data Type	Data Sources	Records Kept
Across domains: What are s	some unanticipated of	consequences of the l	Navigator Program?		
Domain 1: Implementation	To what extent was the Navigator Program (the intervention) implemented and delivered as intended?	Fidelity: quality of the intervention delivery, capturing the nature of what was delivered and not just the specific activities	Interviews Non-participant observation Research and implementation team meetings Documentation from planning phase	Interviews with HOCs, hospital physicians and staff, and community service providers, who interact with the Navigator Program, and with the implementation team Bi-weekly research team meetings; meetings with HOC and implementation team Team records	Audio recordings and transcripts, field notes and memos, meeting notes, and memos about team records
	What was delivered in practice?	Dose: amount of and type of activity	Participant interactions with intervention: number and nature of interactions between the HOCs and participants, community service providers, and healthcare team for each participant	HOC patient chart for all study participants in the intervention arm Meetings with HOCs and implementation team to discuss participant discharge from program	Chart review and meeting notes
Domain 2: Mechanisms 2a. Mechanisms of Impact and Change	 What were the key ingredients and elements of the intervention? Which elements of the intervention supported meeting intervention goals? Which elements of the intervention challenged meeting intervention goals? 	Mechanisms of impact and change (e.g. trust and rapport, relationship-building, communication, etc.) will be explored qualitatively	Interviews Non-participant observation Research and implementation team meetings	Interviews with HOCs, hospital physicians and staff, and community service providers, who interact with the Navigator Program, and with study participants in both the intervention and control arms Shadowing HOCs during their day-to-day workflow in the hospital and in the community Bi-weekly research team meetings and meetings with HOCs and implementation team	Audio recordings and transcripts, field notes and memos, and meeting notes
2b. Mechanisms of Implementation	What were the barriers and facilitators to	Mechanisms of implementation (e.g. acceptability of the	Interviews Non-participant	Interviews with HOCs; with implementation team, with hospital physicians and staff, and	Audio recordings and transcripts, field notes and memos, and meeting notes

Page 1	8 of 31
--------	---------

1 2	
3	Γ
4 5	
6	
7	
8 9	
10	
11 12	
13	
14	
15 16	
17	
18	
20	
21	
22 23	
24	
25	
26 27	
28	
29	
30 31	
32	
33 24	
34 35	
36	
37 38	
39	
40	
41 42	
43	
44	
45 46	
47	

	implementing the intervention?	intervention in the implementation setting) will be explored qualitatively	observation Research and implementation team meetings	community service providers, who interact with the Navigator program Shadowing HOCs during their day-to-day workflow in the hospital and in the community Bi-weekly research team meetings; meetings with HOC and implementation team	
Domain 3: Context	What features of context influenced the intervention implementation and reaching intervention goals?	Characteristics of implementation setting (e.g. hospital services)	Interviews Research and implementation team meetings Documentation from planning phase	Interviews with HOCs, implementation team, hospital physicians and staff, and community service providers, who interact with the Navigator Program Bi-weekly research team meetings and meetings with HOCs and implementation team Team records	Audio recordings and transcripts, field notes and memos, meeting notes, and memos about team records
	How do features of context influence intervention implementation and the activities and services delivered? How do features of the intervention shape the implementation context?	The dynamic influence between multiple domains of the internal and external domains of context (e.g. organizational setting, socioeconomic context, and community resources) and implementation and program activities delivered	Interviews Non-participant observation Research and implementation team meetings Documentation from planning phase	Interviews with HOCs, hospital physicians and staff, and community service providers, who interact with the Navigator Program, and with study participants in both the intervention and control arms Shadowing HOCs during their day-to-day workflow in the hospital and in the community Bi-weekly research team meetings and meetings with HOCs and implementation team Team records	Audio recordings and transcripts, field notes and memos, meeting notes, and memos about team records

Page 19 of 31

BMJ Open

Quantitative data from chart review will be analyzed descriptively to understand intervention fidelity and dose. All qualitative data will be analyzed as data are collected. Interviews, field notes, and NPO will be analyzed separately and then integrated to inform each other on an ongoing basis. Analyses will be conducted by multiple members of the research team and guided by a thematic analysis approach. These qualitative data will be transcribed, notable excerpts coded, and similar codes grouped into themes.⁵⁷ Field notes will be used as initial points of analysis and to contextualize interview data.

Finally, mixed-methods analyses will employ "following a thread" and "triangulation" approaches to bringing quantitative and qualitative data sets together.⁵⁸ Following separate but concurrent initial analyses of quantitative and qualitative components, key themes and interesting data points arising in one data set will be followed across and explored in other data sets. Ultimately, the data sets will be integrated for interpretation and facilitating the identification of "meta-themes" that cut across the data sets. Data source triangulation and researcher triangulation will enhance reliability of findings and provide a more complete picture.⁵⁹ Analyses throughout will also pay particular attention to the ways in which intersecting factors such as sex, gender identity, race, ethnicity, sexual orientation, culture, religion, geography, education, disability, and income shape the experiences of participants during the intervention.

Ethics and Dissemination

Ethics Approval

This study has been approved by the Unity Health Toronto Research Ethics Board (REB). All changes to the study protocol are communicated to and receive approval from the REB before implementation

Participant Safety

Study participants who are assigned to the intervention arm will receive the Navigator Program and may directly benefit from HOC services. Study participants in the usual care arm will not receive any direct benefits.

BMJ Open

Involvement in this research poses minimal risks to participants. The baseline and 30-day interviews do not involve questions that are anticipated to cause emotional distress among participants. There is still a possibility that some participants may find certain interview questions to be challenging or uncomfortable. However, participants may decline to answer specific questions and participants may withdraw from the study at any point in time. Should an individual choose to withdraw from the study entirely, they will keep any honorariums, will still have access to usual care, and may request that their information collected up to that point be destroyed.

Dissemination

Study findings will be rapidly communicated to hospital leadership, healthcare systems, community partners, and the City of Toronto Shelter, Support, and Housing Administration Division. Other key outputs include academic publications, community reports, conference presentations, and a Town Hall that will convene people with lived experience of homelessness, hospital staff, community experts, policy makers, shelter managers and staff, researchers, and public health partners to discuss results and implications.

Data Protection and Retention

The research team will make every effort to keep personal health information private and confidential in accordance with all applicable privacy legislation, including the Personal Health Information Protection Act of Ontario. All participant data that is recorded for study purposes will be de-identified with a random unique study identifier number instead of any personally identifying information. A Master Linking Log with participant identifiers will be stored on a secure computer server in a password protected file. This file will only be made available to designated members of the research team. Research assistants conducting follow-up interviews will only have access to the name of participants and their unique study identifier.

All study data will be kept on a secure hospital server that cannot be accessed by anyone outside of the research team. Only authorized members of the research team will have access to study data. All study data will be kept for a period of seven years from the end of the study and then destroyed. The research team will protect study data and keep all information confidential to the

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

greatest extent possible by law.

Patient and Public Involvement

The Navigator Program was reviewed by the Community Expert Group (CEG) at the MAP Centre for Urban Health Solutions, Unity Health Toronto. This group is composed of diverse individuals with lived experience of homelessness. The CEG will continue to provide guidance and input on study findings and knowledge translation and exchange.

to beet eview only

Competing Interests:

The authors have no competing interests.

Funding:

This work was supported by the St. Michael's Foundation and the Canadian Institutes of Health Research (grant FDN-167263). The funders had no role in the analysis and interpretation of the data or the preparation, review, and approval of the manuscript. The views expressed in this publication are the views of the authors and do not necessarily reflect those of the funders.

Contributor Statement:

SWH conceived of the study. ML, KFP, and SWH led the study design and protocol development. ML, KFP, CP, RB, and SWH designed the survey instruments. CP, RB, and SV are leading recruitment, data collection, and data processing. FE and AR are leading the delivery of the intervention. ML and RN wrote statistical analysis plans and will be conducting statistical analyses. JJ led the conceptualization and development of the mixed-methods process evaluation, with contributions from ML, KFP, OD, and SWH. All authors contributed to refinement of the study protocol. ML drafted the manuscript, and all authors reviewed and approved the final manuscript.

Refe	rences
1.	Gaetz S, Dej E, Richter T, Redman M. The State of Homelessness in Canada 2016.; 2016.
	https://homelesshub.ca/sites/default/files/SOHC16_final_20Oct2016.pdf. Accessed April
	18, 2022.
2.	Liu M, Hwang SW. Health care for homeless people. <i>Nat Rev Dis Prim</i> . 2021;7(1):5.
	doi:10.1038/s41572-020-00241-2
3.	Hwang SW, Wilkins R, Tjepkema M, O'Campo PJ, Dunn JR. Mortality among residents
	of shelters, rooming houses, and hotels in Canada: 11 Year follow-up study. BMJ.
	2009;339(7729):1068. doi:10.1136/bmj.b4036
4.	Aldridge RW, Story A, Hwang SW, et al. Morbidity and mortality in homeless
	individuals, prisoners, sex workers, and individuals with substance use disorders in high-
	income countries: a systematic review and meta-analysis. Lancet. 2018;391(10117):241-
	250. doi:10.1016/S0140-6736(17)31869-X
5.	Hwang SW. Mortality among men using homeless shelters in Toronto, Ontario. JAMA.
	2000;283(16):2152-2157. doi:10.1001/jama.283.16.2152
6.	Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries:
	Descriptive epidemiology, health consequences, and clinical and policy recommendations
	Lancet. 2014;384(9953):1529-1540. doi:10.1016/S0140-6736(14)61132-6
7.	Gutwinski S, Schreiter S, Deutscher K, Fazel S. The prevalence of mental disorders
	among homeless people in high-income countries: An updated systematic review and
	meta-regression analysis. PLOS Med. 2021;18(8):e1003750.
	doi:10.1371/journal.pmed.1003750
8.	Liu M, Luong L, Lachaud J, Edalati H, Reeves A, Hwang SW. Adverse childhood
	experiences and related outcomes among adults experiencing homelessness: a systematic
	review and meta-analysis. Lancet Public Heal. September 2021. doi:10.1016/S2468-
	2667(21)00189-4
9.	Kushel MB, Gupta R, Gee L, Haas JS. Housing instability and food insecurity as barriers
	to health care among low-income Americans. J Gen Intern Med. 2006;21(1):71-77.
	doi:10.1111/j.1525-1497.2005.00278.x
10.	Kushel MB, Vittinghoff E, Haas JS. Factors associated with the health care utilization of
	homeless persons. JAMA. 2001;285(2):200-206. doi:10.1001/jama.285.2.200

11. Hwang SW. Homelessness and health. CMAJ. 2001. doi:10.1177/1359105307080576

- Gelberg L, Gallagher TC, Andersen RM, Koegel P. Competing priorities as a barrier to medical care among homeless adults in Los Angeles. *Am J Public Health*. 1997;87(2):217-220. doi:10.2105/AJPH.87.2.217
- Campbell DJT, O'Neill BG, Gibson K, Thurston WE. Primary healthcare needs and barriers to care among Calgary's homeless populations. *BMC Fam Pract*. 2015;16(1):139. doi:10.1186/s12875-015-0361-3
- Khandor E, Mason K, Chambers C, Rossiter K, Cowan L, Hwang SW. Access to primary health care among homeless adults in Toronto, Canada: Results from the street health survey. *Open Med.* 2011;5(2):94-103. /pmc/articles/PMC3148004/?report=abstract. Accessed July 28, 2020.
- White BM, Newman SD. Access to Primary Care Services Among the Homeless: A Synthesis of the Literature Using the Equity of Access to Medical Care Framework. J Prim Care Community Health. 2015;6(2):77-87. doi:10.1177/2150131914556122
- O'Toole TP, Buckel L, Bourgault C, et al. Applying the chronic care model to homeless veterans: effect of a population approach to primary care on utilization and clinical outcomes. *Am J Public Health*. 2010;100(12):2493-2499. doi:10.2105/AJPH.2009.179416
- Basu S, Berkowitz SA, Phillips RL, Bitton A, Landon BE, Phillips RS. Association of Primary Care Physician Supply with Population Mortality in the United States, 2005-2015. JAMA Intern Med. 2019;179(4):506-514. doi:10.1001/jamainternmed.2018.7624
- Kushel MB, Perry S, Bangsberg D, Clark R, Moss AR. Emergency department use among the homeless and marginally housed: Results from a community-based study. *Am J Public Health*. 2002;92(5):778-784. doi:10.2105/AJPH.92.5.778
- Miyawaki A, Hasegawa K, Figueroa JF, Tsugawa Y. Hospital Readmission and Emergency Department Revisits of Homeless Patients Treated at Homeless-Serving Hospitals in the USA: Observational Study. *J Gen Intern Med.* 2020;35(9):2560-2568. doi:10.1007/s11606-020-06029-0
- Khatana SAM, Wadhera RK, Choi E, et al. Association of Homelessness with Hospital Readmissions—an Analysis of Three Large States. *J Gen Intern Med.* 2020;35(9):2576-2583. doi:10.1007/s11606-020-05946-4
- 21. Liu M, Richard L, Campitelli MA, et al. Hospitalizations During the COVID-19 Pandemic

Page 25 of 31

BMJ Open

3		Among Recently Homeless Individuals: a Retrospective Population-Based Matched
5		Cohort Study. J Gen Intern Med 2022. April 2022:1-10. doi:10.1007/S11606-022-07506-4
6 7	22.	Wang A, Pridham KF, Nisenbaum R, Pedersen C, Brown R, Hwang SW. Factors
8		Associated with Readmission Among General Internal Medicine Patients Experiencing
9 10		Homelessness I Gen Intern Med January 2021:1-7 doi:10.1007/s11606-020-06483-w
11 12	22	Doron KM Baging KT Jacomagai AL Cunningham A Juhanvik KL Jang CV The
12 13	23.	Doran KM, Ragins KT, facomacci AL, Cumingham A, Jubanyik KJ, Jenq GT. The
14 15		revolving hospital door: Hospital readmissions among patients who are homeless. Med
16		<i>Care</i> . 2013;51(9):767-773. doi:10.1097/MLR.0b013e31829fafbb
17 18	24.	Kripalani S, LeFevre F, Phillips CO, Williams M V., Basaviah P, Baker DW. Deficits in
19		communication and information transfer between hospital-based and primary care
20 21		physicians: Implications for patient safety and continuity of care. JAMA. 2007;297(8):831-
22		841. doi:10.1001/jama.297.8.831
23 24	25	Auerbach AD Kripalani S Vasilevskis EE et al Preventability and causes of
25		readmissions in a national cohort of general medicine nations. <i>IAMA Intern Med</i>
26 27		2016.176(A):484.402 doi:10.1001/jourgintemmed.2015.7862
28	• •	2016;1/6(4):484-493. doi:10.1001/jamainternmed.2015./863
29 30	26.	Misky GJ, Wald HL, Coleman EA. Post-hospitalization transitions: Examining the effects
31 32		of timing of primary care provider follow-up. J Hosp Med. 2010;5(7):392-397.
33		doi:10.1002/jhm.666
34 35	27.	Brooke BS, Stone DH, Cronenwett JL, et al. Early primary care provider follow-up and
36		readmission after high-risk surgery. JAMA Surg. 2014;149(8):821-828.
37 38		doi:10.1001/jamasurg.2014.157
39	28.	Hernandez AF. Greiner MA. Fonarow GC. et al. Relationship between early physician
40 41		follow-up and 30-day readmission among medicare beneficiaries hospitalized for heart
42		foilure 14M4 2010:202(17):1716 1722 doi:10.1001/jama.2010.522
43 44	•	Tanure. JAMA. 2010,505(17).1710-1722. doi:10.1001/jama.2010.555
45 46	29.	Greysen SR, Allen R, Lucas GI, Wang EA, Rosenthal MS. Understanding transitions in
47		care from hospital to homeless shelter: A mixed-methods, community-based participatory
48 49		approach. J Gen Intern Med. 2012;27(11):1484-1491. doi:10.1007/s11606-012-2117-2
50	30.	Gunner E, Chandan SK, Yahyouche A, et al. Provision and accessibility of primary
51 52		healthcare services for people who are homeless: a qualitative study of patient
53		perspectives in the UK. Br J Gen Pract. 2019;69(685):e526.
54 55		doi:10.3399/BJGP19X704633
56		
57 58		

4 5

6

7 8

9 10

11

12 13

14 15

16 17

18

19 20

21 22

23

24 25

26 27

28 29

30

31 32

33 34

35 36

37

38 39

40 41

42

43 44

45 46

47 48

49

50 51

52 53

54 55

60

31. Jenkinson JIR, Hwang SW, Strike C, Di Ruggiero E. "We don't have a good system for people who don't have a home and don't need a hospital": Contextualizing the hospital discharge process for people experiencing homelessness in Toronto, Canada. SSM - Qual Res Heal. 2022;2:100056. doi:10.1016/J.SSMQR.2022.100056 32. Pottie K, Kendall CE, Aubry T, et al. Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience. CMAJ. 2020;192(10):E240-E254. doi:10.1503/cmaj.190777 McCormack RP, Hoffman LF, Wall SP, Goldfrank LR. Resource-limited, collaborative 33. pilot intervention for chronically homeless, alcohol-dependent frequent emergency department users. Am J Public Health. 2013;103(SUPPL. 2):S221. doi:10.2105/AJPH.2013.301373 Nelson G, Aubry T, Lafrance A. A review of the literature on the effectiveness of housing 34. and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless. Am J Orthopsychiatry. 2007;77(3):350-361. doi:10.1037/0002-9432.77.3.350 35. Sadowski LS, Kee RA, Vanderweele TJ, Buchanan D. Effect of a housing and case management program on emergency department visits and hospitalizations among chronically III homeless adults a randomized trial. JAMA. 2009;301(17):1771-1778. doi:10.1001/jama.2009.561 36. De Vet R, Van Luijtelaar MJA, Brilleslijper-Kater SN, Vanderplasschen W, Beijersbergen MD, Wolf JRLM. Effectiveness of case management for homeless persons: A systematic review. Am J Public Health. 2013;103(10):e13. doi:10.2105/AJPH.2013.301491 Tomita A, Herman DB. The role of a critical time intervention on the experience of 37. continuity of care among persons with severe mental illness following hospital discharge. J Nerv Ment Dis. 2015;203(1):65. doi:10.1097/NMD.0000000000224 38. Tomita A, Herman DB. The impact of critical time intervention in reducing psychiatric rehospitalization after hospital discharge. Psychiatr Serv. 2012;63(9):935-937. doi:10.1176/APPI.PS.201100468 39. Herman DB, Conover S, Gorroochurn P, Hinterland K, Hoepner L, Susser ES. Randomized trial of critical time intervention to prevent homelessness after hospital discharge. Psychiatr Serv. 2011;62(7):713-719. doi:10.1176/PS.62.7.PSS6207 0713

Page 27 of 31

BMJ Open

2		
3	40.	Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions:
4 5		Medical Research Council guidance. BMJ. 2015;350. doi:10.1136/bmj.h1258
6 7	41.	Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and
8		evaluating complex interventions. The new Medical Research Council guidance <i>BMJ</i>
9 10		2008-337(7676)-979-983 doi:10.1136/bmi.a1655
11	40	
12	42.	Canadian Observatory on Homelessness. Canadian Definition of Homelessness. Toronto;
14 15		2012.
15	43.	Stuebe A, Auguste T, Gulati M. ACOG Committee Opinion No. 736: Optimizing
17 19		Postpartum Care. Obstet Gynecol. 2018;131(5):E140-E150.
19		doi:10.1097/AOG.00000000002633
20 21	44.	Benjenk I, Chen J. Variation of follow-up rate after psychiatric hospitalization of
22		Medicare beneficiaries by hospital characteristics and social determinants of health. Am J
23 24		Geriatr Psychiatry 2019:27(2):138 doi:10.1016/J.JAGP.2018.08.006
25	45	Suresh K An overview of randomization techniques: An unbiased assessment of outcome
26 27	ч.Э.	in clinical research. Likew Derved Sci 2011.4(1):9, 11, doi:10.4102/0074.1209.92252
28		In clinical research. <i>J Hum Reprod Sci</i> . 2011;4(1):8-11. doi:10.4103/09/4-1208.82352
29 30	46.	Schull MJ, Azimaee M, Marra M, et al. ICES: Data, Discovery, Better Health. Int J Popul
31 22		Data Sci. 2019;4(2). doi:10.23889/IJPDS.V4I2.1135
33	47.	Purkey E, MacKenzie M. Experience of healthcare among the homeless and vulnerably
34 35		housed a qualitative study: Opportunities for equity-oriented health care. Int J Equity
36		Health. 2019;18(1):1-7. doi:10.1186/s12939-019-1004-4
37 38	48.	Parry C, Mahoney E, Chalmers SA, Coleman EA. Assessing the quality of transitional
39		care: further applications of the care transitions measure. <i>Med Care</i> . 2008;46(3):317-322.
40 41		doi:10.1097/MLR.0B013F3181589BDC
42 43	<i>4</i> 9	Moon SL Lee WY Hwang IS Hong VP Morisky DF Accuracy of a screening tool for
44	ч).	intoin 35, Lee w 1, Hwang 55, Hong 11, Monsky DL. Accuracy of a screening tool for
45 46		medication adherence: A systematic review and meta-analysis of the Morisky Medication
47		Adherence Scale-8. <i>PLoS One</i> . 2017;12(11). doi:10.1371/journal.pone.0187139
48 49	50.	Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L
50		compared to the EQ-5D-3L across eight patient groups: A multi-country study. Qual Life
51		Res. 2013;22(7):1717-1727. doi:10.1007/s11136-012-0322-4
53 54	51.	Kangovi S, Mitra N, Grande D, et al. Patient-centered community healthworker
55		ntervention to improve posthospital outcomes: A randomized clinical trial. JAMA Intern
56 57		
58		

Med. 2014;174(4):535-543. doi:10.1001/jamainternmed.2013.14327

- Stergiopoulos V, Hwang SW, Gozdzik A, et al. Effect of scattered-site housing using rent supplements and intensive case management on housing stability among homeless adults with mental illness: A randomized trial. *JAMA*. 2015;313(9):905-915. doi:10.1001/jama.2015.1163
- Fagerland MW, Lydersen S, Laake P. Recommended confidence intervals for two independent binomial proportions. *Stat Methods Med Res*. 2011. doi:10.1177/0962280211415469
- 54. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials A practical guide with flowcharts. *BMC Med Res Methodol*. 2017;17(1):162. doi:10.1186/s12874-017-0442-1
- 55. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013;346. doi:10.1136/BMJ.E7586
- 56. Moore G, Audrey S, Barker M, et al. Process evaluation in complex public health intervention studies: The need for guidance. *J Epidemiol Community Health*. 2014;68(2). doi:10.1136/jech-2013-202869
- 57. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3(2). doi:10.1191/1478088706qp063oa
- 58. O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed methods studies. *BMJ*. 2010;341(7783):1147-1150. doi:10.1136/BMJ.C4587
- 59. Creswell JW. *Qualitative Inquiry and Research Design: Choosing among Five Traditions*. Vol 9.; 1998.

60

E

Final Adjudication

(Yes if C=Yes or

D=Yes)

Yes

Yes

Yes

Yes

No

No

Yes Yes

Yes

Yes

Yes Yes

Yes

No

No Yes

No

No Yes

Yes

Yes

Yes

No No

Yes

No

No

A Detion t 20 day	B Brimary Care	C Adjudication of	
Patient 30-day Interview Self-Report	w Office Report ¹	Adjudication of A and B	Adminis Dat
Yes	Yes	Yes	Y
Yes	Yes	Yes	N
Yes	Yes	Yes	n.
Yes	No	No	Y
Ves	No	No	N
Yes	No	No	n
Ves	nd	Ves	V
Ves	n.d.	Ves	N
Ves	n.d.	Ves	n
No	li.u.	Ves	II. V
No	Vas	Tes Vas	1 N
No	Vas	Tes Vas	n
No	I CS	I CS	II. V
No	No	No	
No	No	No	IN IN
No.	110	No	II.
INO	n.d.	INO	Y
NO	n.d.	NO	N
INO	n.d.	INO	n.
n.d.	Yes	Yes	Y
n.d.	Yes	Yes	Ν
n.d.	Yes	Yes	n.
n.d.	No	No	Y
n.d.	No	No	N
n.d.	No	No	n.
n.d.	n.d.	No	Y
n.d.	n.d.	No	N
n.d.	n.d.	No	n.
n.d. = no data. ¹ The primary care	provider (PCP) offi	ce will be contacted	under an

ler any of the following interview, (2) participant reports no the baseline interview or 30-day interview, or (3) participant misses the 30-day interview AND a PCP is identified at the baseline interview.

2	
2	
3	
4	
5	
6	
7	
, 0	
0	
9	
10	
11	
12	
13	
1/	
14	
15	
16	
17	
18	
19	
20	
20	
21	
22	
23	
24	
25	
26	
20	
27	
28	
29	
30	
31	
32	
22	
22	
34	
35	
36	
37	
38	
20	
72	
40	
41	
42	
43	
44	
45	
ر ب ۸۷	
40	
47	
48	
49	
50	
51	
51	
52	
53	
54	
55	
56	
57	
58	
50	
59	
60	

Appendix Table 2: Detailed Descriptions of Study Instruments

Instrument	Description
EQ-5D-3L and VAS	The EQ-5D-3L is a generic measure of health-related quality of life that has been widely used among the homeless population. The EQ-5D-3L includes five three-level items concerning mobility, self-care, usual activities, pain/discomfort, and anxiety/depression that are weighted to produce a single utility score between 0 and 1.
	The Visual Analogue Scale (VAS) of the EQ-5D-3L will also be included, which will allow participants to rate their overall health, mental health, and physical health from 0 to 100.
	References:
	 Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., & Busschbach, J. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Quality of life research</i>, 22(7), 1717-1727. Stergiopoulos, V., Hwang, S. W., Gozdzik, A., Nisenbaum, R., Latimer, E., Rabouin, D., & At Home/Chez Soi Investigators. (2015). Effect of scattered-site housing using rent supplements and intensive case management on housing stability among homeless adults with mental illness: a randomized trial. <i>JAMA</i>, 313(9), 905-915.
MMAS-8	The MMAS-8 is a validated self-reported measure for medication-taking behavior that has been used among disadvantaged patients and those with chronic illnesses
	The MMAS-8 consists of eight items, the first seven of which are yes/no questions and the last of which is a five-point Likert-scale rating. Each "no" response is rated as "1" and each "yes" is rated as "0" except for item 5, in which each "yes" is rated as "1" and each "no" is rated as "0". For item 8, if a patient chooses response "0", the score is "1" and if they choose response "4", the score is "0". Responses "1, 2, 3" are respectively rated as "0.25, 0.75, 0.75". Total MMAS-8 scores can range from 0 to 8 and are categorized into three levels of adherence: high adherence (score = 8), medium adherence (score of 6 to 8), and low adherence (score < 6).
	References:
	 Moon, S. J., Lee, W. Y., Hwang, J. S., Hong, Y. P., & Morisky, D. E. (2017). Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. <i>PloS one</i>, <i>12</i>(11), e0187139. Feehan, M., Morrison, M. A., Tak, C., Morisky, D. E., DeAngelis, M. M., & Munger, M. A. (2017). Factors predicting self-reported medication low adherence in a large sample of adults in the US general population: a cross sectional study. <i>BMJ open</i>, <i>7</i>(6), e014435.

CTM-3	The most widely used measure of care transition quality is the Care Transitio Measure (CTM). The CTM-3 is an abbreviated version of the original CTM- which measures the extent to which the healthcare team accomplished essent care processes in preparing the patient for discharge and participating in post- hospital self-care activities.
	 The CTM-3 consists of three items with a four-point scale with responses ran from "Strongly Disagree" (1) to "Strongly Agree" (4) to the following question 3. During this hospital stay, staff took my preferences into account in deciding what my healthcare needs would be when I left. When I left the hospital, I had a good understanding of the things I w responsible for in managing my health. When I left the hospital, I clearly understood the purpose for taking e my medications
	 Items are scored by summing the responses and then linear transforming to a range. References: Parry, C., Mahoney, E., Chalmers, S. A., & Coleman, E. A. (2008). Assessing the quality of transitional care: further applications of the ortransitions measure. <i>Medical care</i>, 317-322. Coleman, E. A., Smith, J. D., Frank, J. C., Eilertsen, T. B., Thiare, J. Kramer, A. M. (2002). Development and testing of a measure designed assess the quality of care transitions. <i>International journal of integratic care</i>, 2.
RAND Course of Homelessness Scale	 Developed specifically for homeless populations, the RAND scale is a five-it index of self-reported difficulty in meeting the following subsistence needs of the past 30 days: frequency of difficulty in finding shelter, enough to eat, clot a place to wash, and a place to use the bathroom. Possible responses to each i are never (1), rarely (2), sometimes (3), or usually (4) with total scores betwe 20. Reference: Gelberg, L., Gallagher, T. C., Andersen, R. M., & Koegel, P. (1997). Competing priorities as a barrier to medical care among homeless ad Los Angeles. <i>American journal of public health</i>, 87(2), 217-220.

BMJ Open

BMJ Open

Navigator Program for hospitalized adults experiencing homelessness: protocol for a pragmatic randomized controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-065688.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Nov-2022
Complete List of Authors:	Liu, Michael; Harvard Medical School; MAP Centre for Urban Health Solutions Pridham, Katherine; MAP Centre for Urban Health Solutions Jenkinson, Jesse; Unity Health Toronto, MAP Centre for Urban Health Solutions Nisenbaum , Rosane ; St Michael's Hospital, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute; University of Toronto Dalla Lana School of Public Health Richard, Lucie; Unity Health Toronto, Pedersen, Cheryl; MAP Centre for Urban Health Solutions Brown, Rebecca; MAP Centre for Urban Health Solutions Virani, Sareeha; MAP Centre for Urban Health Solutions Ellerington, Fred; St Michael's Hospital Ranieri, Alyssa; St Michael's Hospital Dada, Oluwagbenga; MAP Centre for Urban Health Solutions To, Matthew; University of Toronto Fabreau, Gabriel; University of Calgary , Medicine McBrien, Kerry; University of Calgary Cumming School of Medicine, Family Medicine Stergiopoulos, Vicky; Centre for Addiction and Mental Health Palepu , Anita; The University of British Columbia Hwang, Stephen.; St Michael's Hospital, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute; University of Toronto Department of Medicine, Division of General Internal Medicine
Primary Subject Heading :	Public health
Secondary Subject Heading:	Epidemiology, Health services research, General practice / Family practice, Health policy
Keywords:	GENERAL MEDICINE (see Internal Medicine), Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PUBLIC HEALTH

1	
2	
4	SCHOLAR ONE [™]
5	Manuscripts
6	
7	
8 9	
10	
11	
12	
13	
14	
16	
17	
18	
19	
20	
21	
23	
24	
25	
26	
27	
29	
30	
31	
32	
33	
34 35	
36	
37	
38	
39	
40 41	
42	
43	
44	
45	
40 47	
48	
49	
50	
51	
⊃∠ 53	
54	
55	
56	
57	
50 59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Navigator Program for hospitalized adults experiencing homelessness: protocol for a pragmatic randomized controlled trial

Michael Liu, MPhil^{1,2}, Katherine Francombe Pridham, MSW¹, Jesse Jenkinson, PhD¹, Rosane

Nisenbaum, PhD^{1,3}, Lucie Richard, MA¹, Cheryl Pedersen, MSc¹, Rebecca Brown, BA¹, Sareeha

Virani, BSc¹, Fred Ellerington, BA⁴, Alyssa Ranieri, MSW⁴, Oluwagbenga Dada, MSc¹,

Matthew J. To, MD^{1,5}, Gabriel E. Fabreau, MD, MPH^{6,7}, Kerry A. McBrien, MD, MPH^{6,8}, Vicky Stergiopoulos, MD, MHSc^{9,10}, Anita Palepu, MD, MPH^{11,12}, Stephen W. Hwang, MD, MPH^{1,4}

¹MAP Centre for Urban Health Solutions, Unity Health Toronto, Ontario, Canada

²Harvard Medical School, Boston, Massachusetts, United States of America

³Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Ontario, Canada

⁴Division of General Internal Medicine, St. Michael's Hospital, Unity Health Toronto, Ontario, Canada

⁵Division of Family and Community Medicine, University of Toronto, Ontario, Canada

⁶Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Canada

⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada

⁸Department of Family Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada

⁹Centre for Addiction and Mental Health, Ontario, Canada

¹⁰Department of Psychiatry, Faculty of Medicine, University of Toronto, Ontario, Canada

¹¹Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, British Columbia, Canada

¹²School of Population and Public Health, University of British Columbia, British Columbia, Canada
1	
ן ר	
2	
5	Correspondence to:
4	Stephen W. Hwang, MD, MPH
5	MAP Centre for Urban Health Solutions
6	
7	Unity Health Toronto
8	Toronto, Ontario, Canada
9	Stephen.Hwang@unityhealth.to
10	
11	Ward Courts 4000 (Main Tout) 204 (Abstract)
12	word Count: 4000 (Main Text), 294 (Abstract)
13	
14	Keywords:
15	Homeless Persons: Health Services: Randomized Controlled Trial: Hospitalizations:
15	Dadmissions: Transitions of Cara
10	Readinissions, mansholis of Cale
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
27	
22	
24	
34 25	
35	
36	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
57	
52	
55	
54	
55	
56	
57	
58	
59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Abstract

Introduction: People experiencing homelessness suffer from poor outcomes after hospitalization due to systemic barriers to care, suboptimal transitions of care, and intersecting health and social burdens. Case management programs have been shown to improve housing stability, but their effects on broad post-hospital outcomes in this population have not been rigorously evaluated. The Navigator Program is a Critical Time Intervention case management program that was developed to help homeless patients with their post-discharge needs and to link them with community-based health and social services. This randomized controlled trial examines the impact of the Navigator Program on post-hospital outcomes among adults experiencing homelessness.

Methods and analysis: This is a pragmatic randomized controlled trial testing the effectiveness of the Navigator Program at an urban academic teaching hospital and an urban community teaching hospital in Toronto, Canada. Six hundred forty adults experiencing homelessness who are admitted to the hospital will be randomized to receive support from a Homeless Outreach Counsellor for 90 days after hospital discharge or to usual care. The primary outcome is follow-up with a primary care provider (physician or nurse practitioner) within 14 days of hospital discharge. Secondary outcomes include post-discharge mortality or readmission, number of days in hospital, number of emergency department visits, self-reported care transition quality, and difficulties meeting subsistence needs. Quantitative outcomes are being collected over a 180-day period through linked patient-reported and administrative health data. A parallel mixed-methods process evaluation will be conducted to explore intervention context, implementation, and mechanisms of impact.

Ethics and dissemination: Ethics approval was obtained from the Unity Health Toronto Research Ethics Board. Participants will be required to provide written informed consent. Results of the main trial and process evaluation will be reported in peer-reviewed journals and shared with hospital leadership, community partners, and policy makers.

Trial registration number: ClinicalTrials.gov, NCT04961762.

BMJ Open

Strengths and limitations of this study

- The Navigator Program is a patient-centered case management intervention informed by a prior prospective cohort study and designed in tandem with community partners, healthcare teams, and people with lived experience of homelessness.
- Linkage of patient-reported data with administrative health data allows for rigorous assessment of a much wider range of post-hospital outcomes relative to previous case management studies for people experiencing homelessness.
- This randomized controlled trial is accompanied by a parallel mixed-methods process evaluation that will investigate intervention implementation, causal mechanisms, study context, participant experiences, and outcomes.
- Blinding of participants, Homeless Outreach Counsellors, and healthcare teams is not possible given the active and collaborative nature of the intervention.
- This study takes place at an urban academic teaching hospital and an urban community teaching hospital in Toronto, Canada, and findings may not be generalizable to individuals experiencing homelessness in other contexts and settings.

Introduction

Background and rationale

More than 235,000 Canadians experience homelessness annually, of which 27% are women, 19% are youth, and a growing number are identifying as racial, ethnic, sexual, and gender minorities.^{1,2} This population experiences disproportionate intersecting physical, mental, and social burdens that greatly increase morbidity and mortality relative to the general population.^{3–5} For example, rates of acute and chronic physical health problems, trauma, mental illness, and substance use are much higher among homeless adults.^{6–8}

Homeless individuals often experience substantial barriers to obtaining health care and frequently suffer from unmet health needs.^{9–11} Many have other immediate competing priorities such as securing food and shelter that preclude consistent engagement with healthcare services.^{12,13} Homeless individuals are also much less likely to have a primary care provider (PCP) or usual source of care compared to the general population.^{14,15} Lack of primary care likely contributes to poor outcomes among the homeless population, given that access to primary care is associated with lower mortality and reductions in unnecessary emergency department (ED) visits and hospital admissions.^{16,17} Indeed, there is abundant evidence suggesting that homeless adults rely heavily on acute care services, and rates of ED visits and hospitalizations are much higher among homeless versus non-homeless adults.^{18–21} A related problem is the high rate of hospital readmissions among homeless adults.^{18,19,22,23} Many of these readmissions are thought to be potentially preventable with more complete treatment and better coordination of health and social services following hospital discharge.^{24,25} In the general population, timely access to primary care follow-up after hospitalization has been consistently associated with lower rates of readmissions.^{26–28} Qualitative studies have also revealed that homeless individuals face unique challenges following discharge from hospital, such as difficulties storing medication, inability to find shelter, and not being provided appropriate discharge instructions.^{29–31} Altogether, systemic barriers to primary care, competing priorities, and poor care transitions all contribute toward poor post-hospital outcomes and reliance on acute care settings among homeless individuals.

Page 7 of 51

BMJ Open

Case management is a core component of care for homeless individuals, serving to help navigate and coordinate health and social services.³² Such programs have been adapted and implemented for several subgroups of homeless individuals, including frequent users of acute healthcare services and those with complex needs and mental illness.^{33–35} Systematic reviews have found that case management is effective in improving housing stability, reducing substance use, and removing barriers to securing employment in this population.^{32,36} However, few studies have rigorously evaluated the effect of case management on broad post-hospital outcomes among homeless patients overall.³⁷ One randomized controlled trial (RCT) of a combined transitional housing, long-term housing, and case management intervention reported reductions in hospitalizations, number of hospital days, and ED visits among homeless adults with chronic illnesses.³⁵ Another more recent RCT of a combined permanent supportive housing and case management intervention found significant reductions in psychiatric ED visits and increases in use of outpatient mental health services.³⁸ However, these studies could not evaluate the independent effects of multiple intervention components and did not assess other post-hospital or patient-reported outcomes. One RCT of a physician-led model of multidisciplinary care coordination, advocacy, and hospital discharge planning found a significant increase in quality of life and reduction in street homelessness, but the intervention had no effect on length of hospital stay or post-discharge acute care utilization.³⁹ However, the study was underpowered with low recruitment and follow-up rates. A smaller RCT of a Critical Time Intervention (CTI) case management program focused specifically on homeless patients with severe mental illness was found to improve continuity of care, prevent homelessness, and reduce psychiatric readmissions following hospital discharge.^{40–42}

Accordingly, this current RCT seeks to investigate the effectiveness of an adapted CTI case management program – the Navigator Program – in improving post-hospital outcomes among adults experiencing homelessness at an urban academic teaching hospital and an urban community teaching hospital in Toronto, Canada. CTI is a time-limited case management program which delivers focused case management at critical times or situations in the lives of clients, such as transitioning from hospital care to community care.³⁶ The Navigator Program features Homeless Outreach Counsellors (HOCs) – whose roles are to create strong links between community services and patients through regular contact, supporting patients in

BMJ Open

following their post-discharge care plans, and helping patients in meeting their health- and social-related competing priorities. This intervention was informed by a recent prospective cohort study conducted at the same hospital, which found that having an active case manager, sending discharge summaries to PCPs, and informal support were associated with reduced readmissions among homeless adults.²² The first HOC position was created in February 2019 and has since been expanded to two positions and adapted through conversations with community partners and hospital staff. Ultimately, the goal of the Navigator Program is to help homeless patients who are discharged from the hospital overcome systemic barriers and discontinuities in care that often result in poor health and high acute care utilization.

Objectives

This RCT seeks to evaluate the effectiveness of the Navigator Program in improving posthospital outcomes among adults experiencing homelessness. It will specifically evaluate outcomes related to PCP follow-up, acute care utilization, difficulties meeting subsistence needs, care transition, and overall health following hospital discharge.

A detailed mixed-methods process evaluation will be conducted alongside the RCT. This evaluation primarily aims to provide a deeper understanding of intervention implementation, mechanisms of change within the intervention, and the way in which the Navigator Program interacts with the internal and external contexts to influence both implementation and RCT outcomes in expected or unexpected ways.^{43,44} This evaluation will also aim to understand the inhospital and post-discharge experiences of participants in the intervention and control arms, exploring differences and similarities qualitatively. It is important to investigate how RCT outcomes are shaped by intervention implementation or by the intervention itself, and to identify which parts of the Navigator Program did or did not work to achieve the intended goals and why.

Methods and analysis

Design and setting

This study is a pragmatic RCT that is being conducted at an urban academic teaching hospital (St. Michael's Hospital) and an urban community teaching hospital (St. Joseph's Health Centre)

BMJ Open

in Toronto, Canada. Recruitment began in October 2021 and total recruitment is estimated to be completed in three years.

Eligibility criteria

To be eligible for the study, patients must meet the following criteria: (1) be 18 years of age or older, (2) be admitted to any medical or surgical service (excluding psychiatry and obstetrics), and (3) be identified as experiencing homelessness (as per the Canadian definition of homelessness) at the time of admission or anytime during the hospital admission.⁴⁵ Patients will be excluded from the study if they meet any of the following criteria: (1) are unable to provide informed consent or (2) were connected with a HOC prior to the initiation of the RCT and have received services from the HOC within 90 days preceding their current admission. Each individual patient can be randomized only once during the study period. Patients admitted to psychiatric and obstetric services are excluded from this study because optimal immediate post-discharge follow-up for these patients should be with specialists rather than with PCPs.^{46,47} Furthermore, recommended follow-up timeframes for these patients are often longer than 14 days, thus rendering the primary outcome inapplicable.

Recruitment and data collection

Clinical or research staff will identify potential participants on weekdays. Once identified, the patient will be asked by a member of their circle of care for permission to be introduced to the research team. The research team will then confirm patient eligibility and explain the purpose, process, risks, and benefits of the study to potential participants. Participants may choose to enroll in the study by providing written informed consent (online supplemental file 1).

A baseline interview will be conducted with participants prior to randomization and as a soon as possible after admission to the hospital upon confirmation of eligibility. Sociodemographic information will be collected, including age, gender, race, Indigenous identity, education level, housing status, and social service utilization. Participants who complete the baseline interview will receive a \$20 CAD gift card to compensate them for their time. Another 30-day interview will take place at least 30 days (but no longer than 50 days) after the discharge date to assess patient-reported post-hospital outcomes. At this time, the research team will contact PCPs to

ascertain any follow-up visits. Baseline and 30-day interviews will be conducted in person or remotely. Data from interviews will be collected with tablets using electronic surveys hosted by Snap Professional Software.

The research team will also undertake a chart review of hospital records after discharge to ascertain characteristics of the admission, information about discharge, participant health information, and history of alcohol and substance use.

Plans to promote continued participation

Several strategies will be implemented to minimize attrition. At the baseline interview, study participants will be asked to provide detailed contact information, as well as the names and contact information of family, friends, and other service providers who may be contacted if the research team cannot reach the participant directly. In addition to active outreach from the research team, participants will be asked to contact the research team after discharge to schedule a 30-day interview. Participants who contact the research team 2-3 weeks following their discharge to confirm their contact information and schedule the 30-day interview will receive an additional \$10 CAD honorarium upon completion of the interview. Participants who complete the 30-day interview will also receive a \$40 CAD honorarium and reimbursement for any travel-related expenses, when applicable, for the interview.

Randomization

Participants will be randomized by a third-party internet randomization service (<u>randomize.net</u>). The program will assign participants to either the intervention or the usual care arm using permuted-block randomization, with a 1:1 allocation ratio and random permuted block sizes of 6 or 8. This process will maintain balanced group sizes between the intervention and usual care arms at intermediate points in the recruitment process and minimize the possibility of the research team predicting study allocation.⁴⁸

Intervention

Participants randomized to the intervention arm will be assigned to work with an HOC. The HOC will connect with participants as early as possible during the admission and will provide

BMJ Open

support for 90 days after hospital discharge. The period of support may occasionally be extended beyond 90 days for certain patients, if the HOC deems this to be necessary and appropriate. The main role of the HOC is to support continuity and comprehensiveness of care by helping participants follow their post-discharge plans and facilitating strong links with community-based health and social services. Day-to-day HOC activities fall into five main categories: 1) making connections and referrals to community-based providers, 2) supporting and advocating for patients during the hospital stay and discharge process, 3) supporting patients with health-related matters during the post-discharge period, 4) supporting patients with social-related matters during the post-discharge period, and 5) transferring patient-related information to other healthcare and community-based providers (**Table 1**). The intensity and types of support from HOCs will be tailored to the specific needs of the individual.

Usual care

Participants in the usual care arm will be discharged without support from the HOCs. However, all participants will still receive support as usual from Care Transition Facilitators (CTFs) and/or social workers. CTFs and social workers help patients during their hospital stay to arrange discharge plans and make follow-up arrangements. However, unlike HOCs, CTFs and social workers do not typically work with patients after hospital discharge.

The typical discharge process involves counseling from the discharging physician and healthcare team, who make recommendations or appointments for follow-up care as needed. Patients will also be provided with a written discharge summary and prescription(s) as needed. If the patient has an identified PCP, a copy of the discharge summary is emailed to the PCP.

1
2
3
1
-
5
6
/
8
9
10
11
12
13
14
15
16
17
17
10
19
20
21
22
23
24
25
26
27
27
20
29
30
31
32
33
34
35
36
37
38
39
40
40 41
41
42
43
44
45
46
47
48
49
50
51
52
52
57
54 57
55
56
57
58
59

Table 1: Examples of main activities of Homeless Outreach Counsellors

Category	Examples			
1. Connection to Community-Based	Referral to case managers, housing workers, harm reduction services, and shelters			
Providers				
 Patient Advocacy During Hospital Stay and Discharge Process 	 Link to addiction and harm reduction services within hospital and surrounding area Help patients apply for housing, social benefits, and identification Connect to social activities and provide other materials for in-hospital entertainment Participate in creation of discharge plan and support patient/team in the actual discharge process 			
 Health-Related Support After Discharge 	 Remind patients about their medication regimes Arrange medication storage at post-discharge setting Help patients fill prescriptions (direct patients or accompany them to local pharmacies) Help patients with accessing opioid agonist therapy and safer supply Help patients procure medical aides and devices Remind patients about upcoming medical appointments Attend medical appointments with patients Help patients find and connect with primary care providers Help patients arrange for home care, wound care, eye care, and dental care Connect patients to disease-specific programs Purchase medical-related items to help follow through with post-discharge plans 			
 Social-Related Support After Discharge 	 Help patients apply for housing, social benefits, and identification Arrange transportation to post-discharge setting Help patients find alternative shelter based on unique needs 			
5. Information Transfer	 Follow-up with shelters and case managers to ensure that they have the patient discharge plan and are supporting it Ensure that outpatient services are also aware of patient discharge plan and following through with it Ensure that this hospital and other hospitals are aware of the hospitalization and discharge plan 			

BMJ Open

Data linkage

Participant data will be linked to ICES data. ICES is an independent, non-profit research institute funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. As a prescribed entity under Ontario's privacy legislation, ICES is authorized to collect and use health-related data for the purposes of health system analysis, evaluation, and decision support. Secure access to these data is governed by policies and procedures that are approved by the Information and Privacy Commissioner of Ontario.

Data from participants will be linked to ICES administrative health data from 3 years prior to the admission to 1 year following discharge.⁴⁹ PCP visits, outpatient visits, ED visits, inpatient hospitalizations, and mortality will be ascertained from the Ontario Health Insurance Plan (OHIP) Claims Database, Community Health Center Database, Discharge Abstract Database, Same Day Surgery Database, National Ambulatory Care Reporting System, Ontario Mental Health Reporting System databases, and the Registered Persons Database.

Outcomes

The primary outcome is follow-up with a PCP (physician or nurse practitioner) within 14 days of hospital discharge. This outcome was chosen given the unique and substantial barriers to primary care access faced by the homeless population and the fact that timely access to primary care after hospitalization is linked to better outcomes.^{15,50} In-person visits, virtual encounters, and phone calls will all be considered as follow-up with a PCP. The primary outcome will be ascertained through participant self-report at the 30-day interview, phone calls to PCP offices, and verification in the OHIP and Community Health Center Databases at ICES. In the event of discrepancies between these sources of information, we will use pre-specified rules to adjudicate the primary outcome **(online supplemental file 2).**

Several other outcomes will be assessed given the multiple potential effects that are expected from this complex intervention.⁴⁴ Secondary outcomes include a composite measure of all-cause mortality or readmission, total number of days spent in hospital post-discharge, and number of ED visits within 30-, 90-, and 180-days post-discharge. Acute care utilization (readmissions and days in hospital) outcomes will not include labor and delivery visits and planned readmissions. If

BMJ Open

a patient is transferred between services within the hospital, the entire hospital stay will be treated as a single admission. Other secondary outcomes include self-reported quality of care transition (three-item Care Transitions Measure) after hospital discharge and self-reported change in difficulties meeting subsistence needs (RAND Course of Homelessness Scale) at the time of the 30-day interview relative to baseline.^{12,51} Exploratory outcomes include change in health status (EQ-5D-3L) at the time of the 30-day interview relative to baseline, change in quality of life (EQ-5D Visual Analogue Scale) at the time of the 30-day interview relative to baseline, leaving against medical advice at discharge, medication adherence (eight-item Morisky Medication Adherence Scale) at the time of the 30-day interview, connection to a case manager in the community at the time of the 30-day interview, attendance of any non-PCP healthcare appointment within 180-days post-discharge, and time to all-cause mortality or readmission after discharge.^{52,53} Only non-PCP appointments made by the time of discharge and documented in the discharge summary will be assessed for attendance. Only participants that did not previously report contact with a case manager in the 30-days prior to the baseline interview will be eligible for the connection to a case manager outcome. A summary of outcome domains and study instruments is provided in Table 2 and detailed descriptions of study instruments are provided in it. Ryony online supplemental file 3.

Domain	Variables	Instruments
Patient-Reported Outcomes	 Health Status^{a,b} Quality of Life^{a,b} Medication Adherence^b Care Transition Experience^b Difficulties meeting subsistence needs^{a,b} 	 EQ-5D-3L EQ-5D Visual Analogu Scale (VAS) Morisky Medication Adherence Scale 8-item (MMAS-8) Care Transitions Measu 3-item (CTM-3) RAND Course of
Healthcare Utilization	 Follow-up with primary care provider^{b,d} Hospital readmissions within 30-days, 90-days, and 180-days post-discharge^{b,d} Emergency department visits within 30-days, 90-days, and 180-days post-discharge^{b,d} Number of days spent in hospital within 30-days, 90-days, and 180-days post-discharge^{b,d} Number of days spent in hospital within 30-days, 90-days, and 180-days post-discharge^{b,d} Attendance of any non-PCP health care appointment within 180-days post-discharge^{b,d} 	-
Social Service Utilization	Connection to case manager ^b	
Mortality ^d		
^a Self-reported from basel ^b Self-reported from 30-da ^c Collected from discharge ^d Ascertained from admini	ne interview y interview e chart review strative health data	

Sample size

No previous data are available to ascertain 14-day PCP follow-up rates after hospitalization among people experiencing homelessness under usual care. However, a previous study reported that 14-day PCP follow-up rates after hospitalization among low socioeconomic status (SES) patients was ~48%.⁵⁴ An assumption was made that 14-day PCP follow-up rates after hospitalization among people experiencing homelessness under usual care is around 2/3 that of low-SES patients (32%). This study is powered to detect an effect size of 12%, equivalent to a 37.5% increase in relative rate of follow-up with a PCP within 14 days of discharge. With an α of 0.05, 256 participants per study arm will result in an 80% power to test the study hypothesis. Given an estimated 20% attrition rate based on past studies in this population,⁵⁵ a total of 640 participants will be recruited for this study.

Blinding

It will not be possible to blind participants, HOCs, or healthcare teams given the active and collaborative nature of the intervention. However, data collectors and data analysts will be blinded to the allocation of participants. The research team member who performs study allocation for a participant will not be involved in the 30-day follow-up interview for that participant.

Statistical analyses

All analyses will follow the intention-to-treat principle. Sample characteristics will be summarized by descriptive statistics (mean, standard deviation, median, interquartile range, and proportion). We will also construct graphs to explore relationships and estimate correlations between participant characteristics and outcomes. Descriptive comparisons between group baseline characteristics and outcomes will be performed with χ^2 or Fisher exact tests for categorical variables and with t-tests or Wilcoxon rank sum tests for continuous or count variables.

The primary analysis will be performed using the χ^2 test to compare two independent proportions of 14-day PCP follow-up. The difference in proportions (risk difference, RD) and 95% confidence interval (CI) will be estimated using the Wald method.⁵⁶ Two secondary analyses will

Page 17 of 51

BMJ Open

be conducted. The first is a log-binomial regression model including the intervention arm indicator as the covariate. The risk ratio and 95% CI will be estimated from the model. The second is a logistic regression model including the intervention arm indicator as the covariate. The odds ratio (OR) and 95% CI will be estimated from the model. To explore potential subgroup effects, multivariable logistic regression models for the primary outcome will be constructed including each of the following pre-specified covariates, one-at-a-time and with corresponding interaction terms with the intervention arm: age, sex, current illicit drug use, current risky alcohol use, Charlson comorbidity index score, and prior acute care utilization for a mental health reason.

For secondary and exploratory binary outcomes, logistic regression models will be used to estimate ORs and 95% CIs. For count outcomes, Poisson or negative binomial regression models (if over-dispersion is suggested by the data) will be used to estimate rate ratios and 95% CIs. For cross-sectional continuous outcomes, linear regression models will be constructed. For longitudinal continuous outcomes, we will consider linear mixed models or generalized estimating equations, depending on the outcome distribution. Models will include the intervention arm indicator, time (baseline versus 30-day interview), and the interaction of intervention arm by time. A significant interaction will indicate that the change from baseline is different between the study groups. This difference and 95% CI will be estimated. For time to all-cause mortality or readmission after discharge, a survival analysis will be performed. Cumulative event rates will be calculated with the Kaplan-Meier method, with event or censoring times calculated from the date of discharge. Differences in Kaplan-Meier survival curves between the study arms will be assessed using the log-rank test.

Any missing data will be considered, and multiple imputation will be performed if indicated either for the main analyses or as sensitivity analyses.⁵⁷ All analyses will be conducted using R, STATA, and SAS. All statistical tests will be two-sided and a p-value of 0.05 or less will indicate statistical significance. Adjustments will not be conducted for multiple comparisons. This protocol follows guidance from the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT).⁵⁸

BMJ Open

Process evaluation methods and analysis

In keeping with recommendations from the Medical Research Council on Process Evaluations of Complex Interventions,⁴³ we have designed a pragmatic mixed-methods process evaluation that will gather quantitative measures on program activities and qualitative data on how participants experience the intervention and how staff experience its implementation and operationalization. Three domains will be explored in this evaluation: implementation, mechanisms of impact, and context. Multiple data collection methods will be employed to better understand intervention implementation, mechanisms of change, and important contextual influences on the Navigator Program. These methods and their corresponding process evaluation domains, research questions, and data sources are outlined in **Table 3**, and include chart review, non-participant observation (NPO), semi-structured interviews, and field notes. Chart review will include data on the number and nature of interactions between HOCs and participants, community service providers, and healthcare team, collected from a database developed specifically for the Navigator Program. NPO is a process of observing participants and the program setting without actively participating, and can be helpful for assessing the finer details and spirit of implementation, mechanisms of change and program activities, and contexts.⁵⁹ In this study, NPO will entail accompanying the HOCs as they do their day-to-day work at the hospital and in the community. Semi-structured interviews will be conducted with the HOCs (n=2), the implementation team (n=4), hospital physicians and staff (n=25-50), community service providers (n=10-20) that interact with the Navigator Program, and individuals experiencing homelessness enrolled in the study in both the intervention (n=15-25) and control arms (n=15-25)25).

Process Evaluation	Research	Core	Data Type	Data Sources	Records Kept
cross domains: What are so	me unanticipated c	onsequences of the 1	Navigator Program?		
Omain 1: Implementation	To what extent was	Fidelity: quality of the	Interviews	Interviews with HOCs, hospital	Audio recordings and transcripts, field
	the Navigator Program (the intervention) implemented and delivered as intended?	intervention delivery, capturing the nature of what was delivered and not just the specific activities	Non-participant observation Research and implementation team	physicians and staff, and community service providers, who interact with the Navigator Program, and with the implementation team	notes and memos, meeting notes, and memos about team records
	intended.	Do	Documentation from planning phase	Bi-weekly research team meetings; meetings with HOC and implementation team	
			r ··· Or ····	Team records	
	What was delivered in practice?	Dose: amount of and type of activity	Participant interactions with intervention: number and nature of interactions between the HOCs and	HOC patient chart for all study participants in the intervention arm	Chart review and meeting notes
			participants, community service providers, and healthcare team for each participant	Meetings with HOCs and implementation team to discuss participant discharge from program	
Domain 2: Mechanisms 2a. Mechanisms of Impact and Change	What were the key ingredients and elements of the intervention?Which elements of the intervention supported meeting intervention goals?Which elements of the intervention challenged meeting intervention goals?	Mechanisms of impact and change (e.g. trust and rapport, relationship-building, communication, etc.) will be explored qualitatively	Interviews Non-participant observation Research and implementation team meetings	Interviews with HOCs, hospital physicians and staff, and community service providers, who interact with the Navigator Program, and with study participants in both the intervention and control arms Shadowing HOCs during their day-to-day workflow in the hospital and in the community Bi-weekly research team meetings and meetings with HOCs and implementation team	Audio recordings and transcripts, field notes and memos, and meeting notes
2b. Mechanisms of Implementation	What were the barriers and facilitators to	Mechanisms of implementation (e.g. acceptability of the	Interviews Non-participant	Interviews with HOCs; with implementation team, with hospital physicians and staff, and	Audio recordings and transcripts, field notes and memos, and meeting notes

eatures of influenced g intervention intervention conservation implementation implementation implementation implementation se (e.g. hospital servi	he observation he observation Atively Research and implementation team meetings of Interviews setting Research and implementation team meetings Provices) Research and implementation team meetings Documentation from planning phase Documentation from planning phase	community service providers, who interact with the Navigator programShadowing HOCs during their day-to-day workflow in the hospital and in the communityBi-weekly research team meetings; meetings with HOC and implementation teamInterviews with HOCs, implementation team, hospital physicians and staff, and community service providers, who interact with the Navigator ProgramBi-weekly research team meetings and meetings with HOCs and	Audio recordings and transcripts, field notes and memos, meeting notes, and memos about team records
eatures of influenced revention entation and g intervention	of Interviews setting rvices) Research and implementation team meetings Documentation from planning phase	Interviews with HOCs, implementation team, hospital physicians and staff, and community service providers, who interact with the Navigator Program Bi-weekly research team meetings and meetings with HOCs and	Audio recordings and transcripts, field notes and memos, meeting notes, and memos about team records
	6	implementation team Team records	
o features of influence ntionThe dynamic influ between multiple domains of the int and external doma of context (e.g. organizational sett socioeconomic con and community resources) and implementation ar program activities delivered	fluence Interviews le internal Non-participant observation etting, context, Research and implementation team meetings and es Documentation from planning phase	Interviews with HOCs, hospital physicians and staff, and community service providers, who interact with the Navigator Program, and with study participants in both the intervention and control arms Shadowing HOCs during their day-to-day workflow in the hospital and in the community Bi-weekly research team meetings and meetings with HOCs and implementation team Team records	Audio recordings and transcripts, field notes and memos, meeting notes, and memos about team records
or heie??	features of vention resources) and community resources) and implementation program activities delivered	features of vention e implementation and community meetings vention e implementation and program activities delivered Documentation from planning phase	socioeconomic context, features of ventionimplementation team meetingsintervention and control armsfeatures of ventionand community resources) and implementation and program activities deliveredDocumentation from planning phaseShadowing HOCs during their day-to-day workflow in the hospital and in the communityBi-weekly research team meetings and meetings with HOCs and implementation teamBi-weekly research team meetings and meetings with HOCs and implementation team

Page 21 of 51

BMJ Open

Quantitative data from chart review will be analyzed descriptively to understand intervention fidelity and dose. All qualitative data will be analyzed as data are collected. Interviews, field notes, and NPO will be analyzed separately and then integrated to inform each other on an ongoing basis. Analyses will be conducted by multiple members of the research team and guided by a thematic analysis approach. These qualitative data will be transcribed, notable excerpts coded, and similar codes grouped into themes.⁶⁰ Field notes will be used as initial points of analysis and to contextualize interview data.

Finally, mixed-methods analyses will employ "following a thread" and "triangulation" approaches to bringing quantitative and qualitative data sets together.⁶¹ Following separate but concurrent initial analyses of quantitative and qualitative components, key themes and interesting data points arising in one data set will be followed across and explored in other data sets. Ultimately, the data sets will be integrated for interpretation and facilitating the identification of "meta-themes" that cut across the data sets. Data source triangulation and researcher triangulation will enhance reliability of findings and provide a more complete picture.⁶² Analyses throughout will also pay particular attention to the ways in which intersecting factors such as sex, gender identity, race, ethnicity, sexual orientation, culture, religion, geography, education, disability, and income shape the experiences of participants during the intervention.

Patient and public involvement

The Navigator Program was reviewed by the Community Expert Group (CEG) at the MAP Centre for Urban Health Solutions, Unity Health Toronto. This group is composed of diverse individuals with lived experience of homelessness. The CEG will continue to provide guidance and input on study findings and knowledge translation and exchange.

Ethics and dissemination

Ethics approval

This study has been approved by the Unity Health Toronto Research Ethics Board (REB). All changes to the study protocol are communicated to and receive approval from the REB before implementation.

Participant safety

Study participants who are assigned to the intervention arm will receive the Navigator Program and may directly benefit from HOC services. Study participants in the usual care arm will not receive any direct benefits.

Involvement in this research poses minimal risks to participants. The baseline and 30-day interviews do not involve questions that are anticipated to cause emotional distress among participants. There is still a possibility that some participants may find certain interview questions to be challenging or uncomfortable. However, participants may decline to answer specific questions and participants may withdraw from the study at any point in time. Should an individual choose to withdraw from the study entirely, they will keep any honorariums, will still have access to usual care, and may request that their information collected up to that point be destroyed.

Dissemination

Study findings will be rapidly communicated to hospital leadership, healthcare systems, community partners, and the City of Toronto Shelter, Support, and Housing Administration Division. Other key outputs include academic publications, community reports, conference presentations, and a Knowledge Sharing Event that will convene people with lived experience of homelessness, hospital staff, community experts, policy makers, shelter managers and staff, researchers, and public health partners to discuss results and implications.

Data protection and retention

The research team will make every effort to keep personal health information private and confidential in accordance with all applicable privacy legislation, including the Personal Health Information Protection Act of Ontario. All participant data that is recorded for study purposes will be de-identified with a random unique study identifier number instead of any personally identifying information. A Master Linking Log with participant identifiers will be stored on a secure computer server in a password protected file. This file will only be made available to designated members of the research team. Research assistants conducting follow-up interviews will only have access to the name of participants and their unique study identifier.

BMJ Open

All study data will be kept on a secure hospital server that cannot be accessed by anyone outside of the research team. Only authorized members of the research team will have access to study data. All study data will be kept for a period of seven years from the end of the study and then destroyed. The research team will protect study data and keep all information confidential to the greatest extent possible by law.

to beet eview only

Competing interests

The authors have no competing interests.

Funding

This work was supported by the St. Michael's Foundation and the Canadian Institutes of Health Research (grant FDN-167263). The funders had no role in the analysis and interpretation of the data or the preparation, review, and approval of the manuscript. The views expressed in this publication are the views of the authors and do not necessarily reflect those of the funders.

Contributors

SWH conceived of the study. ML, KFP, and SWH led the study design and protocol development. MJT, GEF, KAM, VS, and AP assisted with study design. ML, KFP, CP, RB, and SWH designed the survey instruments. CP, RB, and SV are leading recruitment, data collection, and data processing. FE and AR are leading the delivery of the intervention. ML, RN, and LR wrote statistical analysis plans and will be conducting statistical analyses. JJ led the conceptualization and development of the mixed-methods process evaluation, with contributions from ML, KFP, OD, and SWH. All authors contributed to refinement of the study protocol. ML drafted the manuscript, and all authors reviewed and approved the final manuscript.

Refe	erences
1.	Gaetz S, Dej E, Richter T, Redman M. The State of Homelessness in Canada 2016.; 2016.
	https://homelesshub.ca/sites/default/files/SOHC16_final_20Oct2016.pdf. Accessed April
	18, 2022.
2.	Liu M, Hwang SW. Health care for homeless people. Nat Rev Dis Prim. 2021;7(1):5.
	doi:10.1038/s41572-020-00241-2
3.	Hwang SW, Wilkins R, Tjepkema M, O'Campo PJ, Dunn JR. Mortality among residents
	of shelters, rooming houses, and hotels in Canada: 11 Year follow-up study. BMJ.
	2009;339(7729):1068. doi:10.1136/bmj.b4036
4.	Aldridge RW, Story A, Hwang SW, et al. Morbidity and mortality in homeless
	individuals, prisoners, sex workers, and individuals with substance use disorders in high-
	income countries: a systematic review and meta-analysis. Lancet. 2018;391(10117):241-
	250. doi:10.1016/S0140-6736(17)31869-X
5.	Hwang SW. Mortality among men using homeless shelters in Toronto, Ontario. JAMA.
	2000;283(16):2152-2157. doi:10.1001/jama.283.16.2152
6.	Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries:
	Descriptive epidemiology, health consequences, and clinical and policy recommendations
	Lancet. 2014;384(9953):1529-1540. doi:10.1016/S0140-6736(14)61132-6
7.	Gutwinski S, Schreiter S, Deutscher K, Fazel S. The prevalence of mental disorders
	among homeless people in high-income countries: An updated systematic review and
	meta-regression analysis. PLOS Med. 2021;18(8):e1003750.
	doi:10.1371/journal.pmed.1003750
8.	Liu M, Luong L, Lachaud J, Edalati H, Reeves A, Hwang SW. Adverse childhood
	experiences and related outcomes among adults experiencing homelessness: a systematic
	review and meta-analysis. Lancet Public Heal. September 2021. doi:10.1016/S2468-
	2667(21)00189-4
9.	Kushel MB, Gupta R, Gee L, Haas JS. Housing instability and food insecurity as barriers
	to health care among low-income Americans. J Gen Intern Med. 2006;21(1):71-77.
	doi:10.1111/j.1525-1497.2005.00278.x
10.	Kushel MB, Vittinghoff E, Haas JS. Factors associated with the health care utilization of
	homeless persons. JAMA. 2001;285(2):200-206. doi:10.1001/jama.285.2.200

11. Hwang SW. Homelessness and health. CMAJ. 2001. doi:10.1177/1359105307080576

- Gelberg L, Gallagher TC, Andersen RM, Koegel P. Competing priorities as a barrier to medical care among homeless adults in Los Angeles. *Am J Public Health*. 1997;87(2):217-220. doi:10.2105/AJPH.87.2.217
- Campbell DJT, O'Neill BG, Gibson K, Thurston WE. Primary healthcare needs and barriers to care among Calgary's homeless populations. *BMC Fam Pract*. 2015;16(1):139. doi:10.1186/s12875-015-0361-3
- Khandor E, Mason K, Chambers C, Rossiter K, Cowan L, Hwang SW. Access to primary health care among homeless adults in Toronto, Canada: Results from the street health survey. *Open Med.* 2011;5(2):94-103. /pmc/articles/PMC3148004/?report=abstract. Accessed July 28, 2020.
- White BM, Newman SD. Access to Primary Care Services Among the Homeless: A Synthesis of the Literature Using the Equity of Access to Medical Care Framework. J Prim Care Community Health. 2015;6(2):77-87. doi:10.1177/2150131914556122
- O'Toole TP, Buckel L, Bourgault C, et al. Applying the chronic care model to homeless veterans: effect of a population approach to primary care on utilization and clinical outcomes. *Am J Public Health*. 2010;100(12):2493-2499. doi:10.2105/AJPH.2009.179416
- Basu S, Berkowitz SA, Phillips RL, Bitton A, Landon BE, Phillips RS. Association of Primary Care Physician Supply with Population Mortality in the United States, 2005-2015. JAMA Intern Med. 2019;179(4):506-514. doi:10.1001/jamainternmed.2018.7624
- Miyawaki A, Hasegawa K, Figueroa JF, Tsugawa Y. Hospital Readmission and Emergency Department Revisits of Homeless Patients Treated at Homeless-Serving Hospitals in the USA: Observational Study. *J Gen Intern Med.* 2020;35(9):2560-2568. doi:10.1007/s11606-020-06029-0
- Khatana SAM, Wadhera RK, Choi E, et al. Association of Homelessness with Hospital Readmissions—an Analysis of Three Large States. *J Gen Intern Med.* 2020;35(9):2576-2583. doi:10.1007/s11606-020-05946-4
- Liu M, Richard L, Campitelli MA, et al. Hospitalizations During the COVID-19 Pandemic Among Recently Homeless Individuals: a Retrospective Population-Based Matched Cohort Study. J Gen Intern Med 2022. April 2022:1-10. doi:10.1007/S11606-022-07506-4
- 21. Raven MC, Tieu L, Lee CT, Ponath C, Guzman D, Kushel M. Emergency Department

BMJ Open

2		
3 4		Use in a Cohort of Older Homeless Adults: Results From the HOPE HOME Study. Acad
5		Emerg Med. 2017;24(1):63-74. doi:10.1111/ACEM.13070
6 7	22.	Wang A, Pridham KF, Nisenbaum R, Pedersen C, Brown R, Hwang SW. Factors
8		Associated with Readmission Among General Internal Medicine Patients Experiencing
10		Homelessness. J Gen Intern Med. January 2021:1-7. doi:10.1007/s11606-020-06483-w
11 12	23.	Doran KM, Ragins KT, Iacomacci AL, Cunningham A, Jubanyik KJ, Jenq GY. The
13 14		revolving hospital door: Hospital readmissions among patients who are homeless. Med
15		<i>Care</i> . 2013;51(9):767-773. doi:10.1097/MLR.0b013e31829fafbb
16 17	24.	Kripalani S, LeFevre F, Phillips CO, Williams M V., Basaviah P, Baker DW. Deficits in
18 19		communication and information transfer between hospital-based and primary care
20		physicians: Implications for nations safety and continuity of care JAMA 2007:297(8):831-
21 22		841 doi:10.1001/jama.297.8.831
23	25	Augrhach AD, Kringlani S, Vagilavakia EE, et al. Proventability and equade of
25	23.	Autorian AD, Kinpalan S, Vasnevskis EE, et al. Preventability and causes of
26 27		readmissions in a national conort of general medicine patients. JAMA Intern Med.
28		2016;176(4):484-493. doi:10.1001/jamainternmed.2015.7863
29 30	26.	Misky GJ, Wald HL, Coleman EA. Post-hospitalization transitions: Examining the effects
31		of timing of primary care provider follow-up. J Hosp Med. 2010;5(7):392-397.
32 33		doi:10.1002/jhm.666
34 35	27.	Brooke BS, Stone DH, Cronenwett JL, et al. Early primary care provider follow-up and
36		readmission after high-risk surgery. JAMA Surg. 2014;149(8):821-828.
37 38		doi:10.1001/jamasurg.2014.157
39	28.	Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician
40 41		follow-up and 30-day readmission among medicare beneficiaries hospitalized for heart
42 43		failure $IAMA$ 2010:303(17):1716-1722 doi:10.1001/jama.2010.533
44	20	Crewson SD. Allon D. Lycos CL. Wang FA. Desenthal MS. Understanding transitions in
45 46	29.	Greysen SK, Anen K, Lucas GI, wang EA, Kosenthal MIS. Understanding transitions in
47		care from hospital to homeless shelter: A mixed-methods, community-based participatory
48 49		approach. J Gen Intern Med. 2012;27(11):1484-1491. doi:10.1007/s11606-012-2117-2
50	30.	Gunner E, Chandan SK, Yahyouche A, et al. Provision and accessibility of primary
52		healthcare services for people who are homeless: a qualitative study of patient
53 54		perspectives in the UK. Br J Gen Pract. 2019;69(685):e526.
55		doi:10.3399/BJGP19X704633
56 57		
58		

4 5

6

7 8

9 10

11

12 13

14 15

16 17

18

19 20

21 22

23

24 25

26 27

28 29

30

31 32

33 34

35 36

37

38 39

40 41

42

43 44

45 46

47 48

49

50 51

52 53

54 55

60

31. Jenkinson JIR, Hwang SW, Strike C, Di Ruggiero E. "We don't have a good system for people who don't have a home and don't need a hospital": Contextualizing the hospital discharge process for people experiencing homelessness in Toronto, Canada. SSM - Qual Res Heal. 2022;2:100056. doi:10.1016/J.SSMQR.2022.100056 32. Pottie K, Kendall CE, Aubry T, et al. Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience. CMAJ. 2020;192(10):E240-E254. doi:10.1503/cmaj.190777 McCormack RP, Hoffman LF, Wall SP, Goldfrank LR. Resource-limited, collaborative 33. pilot intervention for chronically homeless, alcohol-dependent frequent emergency department users. Am J Public Health. 2013;103(SUPPL. 2):S221. doi:10.2105/AJPH.2013.301373 Nelson G, Aubry T, Lafrance A. A review of the literature on the effectiveness of housing 34. and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless. Am J Orthopsychiatry. 2007;77(3):350-361. doi:10.1037/0002-9432.77.3.350 35. Sadowski LS, Kee RA, Vanderweele TJ, Buchanan D. Effect of a housing and case management program on emergency department visits and hospitalizations among chronically III homeless adults a randomized trial. JAMA. 2009;301(17):1771-1778. doi:10.1001/jama.2009.561 36. De Vet R, Van Luijtelaar MJA, Brilleslijper-Kater SN, Vanderplasschen W, Beijersbergen MD, Wolf JRLM. Effectiveness of case management for homeless persons: A systematic review. Am J Public Health. 2013;103(10):e13. doi:10.2105/AJPH.2013.301491 Luchenski SA, Dawes J, Aldridge RW, et al. Hospital-based preventative interventions for 37. people experiencing homelessness in high-income countries: A systematic review. eClinicalMedicine. 2022;54. doi:10.1016/j.eclinm.2022.101657 38. Raven MC, Niedzwiecki MJ, Kushel M. A randomized trial of permanent supportive housing for chronically homeless persons with high use of publicly funded services. Health Serv Res. 2020;55(S2):797-806. doi:10.1111/1475-6773.13553 39. Hewett N, Buchman P, Musariri J, et al. Randomised controlled trial of GP-led in-hospital management of homeless people ('Pathway'). Clin Med (Northfield Il). 2016;16(3):223-229. doi:10.7861/CLINMEDICINE.16-3-223

Page 29 of 51

1

BMJ Open

2		
3	40.	Tomita A, Herman DB. The role of a critical time intervention on the experience of
5		continuity of care among persons with severe mental illness following hospital discharge.
6 7		J Nerv Ment Dis. 2015;203(1):65. doi:10.1097/NMD.00000000000224
8	41.	Tomita A, Herman DB. The impact of critical time intervention in reducing psychiatric
9 10		rehospitalization after hospital discharge <i>Psychiatr Serv</i> 2012:63(9):935-937
11 12		doi:10.1176/APPI PS 201100/68
13	40	
14 ⁴	42.	Herman DB, Conover S, Gorroochurn P, Hinterland K, Hoepner L, Susser ES.
16		Randomized trial of critical time intervention to prevent homelessness after hospital
17 18		discharge. Psychiatr Serv. 2011;62(7):713-719. doi:10.1176/PS.62.7.PSS6207_0713
19 ⁴	43.	Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions:
20 21		Medical Research Council guidance. BMJ. 2015;350. doi:10.1136/bmj.h1258
22	44.	Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and
23 24		evaluating complex interventions: update of Medical Research Council guidance. BMJ.
25		2021:374_doi:10_1136/BMJ N2061
20	15	Considian Observatory on Homolossnoss, Canadian Definition of Homolossnoss, Toronto:
28 20	43.	Canadian Observatory on Homelessness. Canadian Definition of Homelessness. Toronto,
30		2012.
31 ⁴	46.	Stuebe A, Auguste T, Gulati M. ACOG Committee Opinion No. 736: Optimizing
33		Postpartum Care. Obstet Gynecol. 2018;131(5):E140-E150.
34 35		doi:10.1097/AOG.00000000002633
36 ⁴	47.	Benjenk I, Chen J. Variation of follow-up rate after psychiatric hospitalization of
37 38		Medicare beneficiaries by hospital characteristics and social determinants of health. Am J
39 40		Geriatr Psychiatry. 2019;27(2):138. doi:10.1016/J.JAGP.2018.08.006
41	48.	Suresh K. An overview of randomization techniques: An unbiased assessment of outcome
42 43		in clinical research J Hum Reprod Sci 2011:4(1):8-11 doi:10.4103/0974-1208.82352
44	40	Schull MI Azimaca M. Marra M. et al. ICES: Data Discovery Potter Health Int I Popul
45 ' 46	49.	Schuli MJ, Azimaee M, Maria M, et al. ICES. Data, Discovery, Better Health. Int J Popul
47		Data Sci. 2019;4(2). doi:10.23889/IJPDS.V4I2.1135
48 49	50.	Purkey E, MacKenzie M. Experience of healthcare among the homeless and vulnerably
50		housed a qualitative study: Opportunities for equity-oriented health care. Int J Equity
51 52		Health. 2019;18(1):1-7. doi:10.1186/s12939-019-1004-4
53	51.	Parry C, Mahoney E, Chalmers SA, Coleman EA. Assessing the quality of transitional
55		care: further applications of the care transitions measure. <i>Med Care</i> . 2008;46(3):317-322.
56 57		
58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
17	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
40	
12	
⊿ד∠ ⊿२	
43 44	
44	
45	
40	
4/	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

doi:10.1097/MLR.0B013E3181589BDC

- Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. *PLoS One*. 2017;12(11). doi:10.1371/journal.pone.0187139
- 53. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. *Qual Life Res.* 2013;22(7):1717-1727. doi:10.1007/s11136-012-0322-4
- Kangovi S, Mitra N, Grande D, et al. Patient-centered community healthworker ntervention to improve posthospital outcomes: A randomized clinical trial. *JAMA Intern Med.* 2014;174(4):535-543. doi:10.1001/jamainternmed.2013.14327
- 55. Stergiopoulos V, Hwang SW, Gozdzik A, et al. Effect of scattered-site housing using rent supplements and intensive case management on housing stability among homeless adults with mental illness: A randomized trial. *JAMA*. 2015;313(9):905-915. doi:10.1001/jama.2015.1163
- 56. Fagerland MW, Lydersen S, Laake P. Recommended confidence intervals for two independent binomial proportions. *Stat Methods Med Res*. 2011. doi:10.1177/0962280211415469
- 57. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials A practical guide with flowcharts. *BMC Med Res Methodol*. 2017;17(1):162. doi:10.1186/s12874-017-0442-1
- 58. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013;346. doi:10.1136/BMJ.E7586
- Moore G, Audrey S, Barker M, et al. Process evaluation in complex public health intervention studies: The need for guidance. *J Epidemiol Community Health*. 2014;68(2). doi:10.1136/jech-2013-202869
- Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3(2). doi:10.1191/1478088706qp063oa
- 61. O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed methods studies. *BMJ*. 2010;341(7783):1147-1150. doi:10.1136/BMJ.C4587
- 62. Creswell JW. *Qualitative Inquiry and Research Design: Choosing among Five Traditions*. Vol 9.; 1998.

BMJ Open

1 2 3 4 5	CLINICAL TRIALS ONTARIO	661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca
7 8	Informed Consent Form for Participation in a Resear	rch Study
9 10 11 12	Study Title : Effect of a Navigator Program on Post-Hospital Outcomes for Pragmatic Randomized Controlled Trial	or Homeless Adults: A
13 14 15	Principal Investigator : Dr. Stephen Hwang, MD MPH, Centre for Urban Michael's Hospital, 416-864-5991(M-F, 9 AM – 5 PM)	Health Solutions, St.
16 17 18 10	Funder: The Navigator program is funded by the St. Michael's Hospital F study is funded by a CIHR Foundation Grant	Foundation and this research
19 20 21	INTRODUCTION	
21 22 23 24 25 26 27 28 29	You are being asked to consider participating in this research study becaus homelessness and have been admitted to St. Michael's Hospital. All research have to participate, and you can withdraw at any time. Before agreeing to study, it is important that you read the information in this consent form. It need to know in order to decide if you wish to take part in the study. If you study doctor ot study staff. You should also be aware that it is possible that Principal Investigator may also be your treating doctor.	se you are experiencing rch is voluntary – you do not take part in this research includes details we think you u have any questions, ask the tt the St. Michael's Hospital
30 31 32 33 34	If you choose to participate in the study, you will need to sign this Letter of Form. You should not sign this form until you are sure you understand the wish to discuss the study with others, such as your case manager, family d close friend.	of Information and Consent information. You may also loctor, a family member, or
35 36	IS THERE A CONFLICT OF INTEREST?	
37 38 39	The study doctors and study staff do not have any conflicts of interest, finate this study or its outcome.	ancial or otherwise, related to
40 41 42 43 44 45 46 47	<u>WHAT IS THE BACKGROUND INFORMATION FOR THIS STUDY?</u> Individuals experiencing homelessness often face significant challenges are services and social supports during and after hospitalization. The Navigate management program - seeks to help participants follow their post-dischar needs, and connect with community-based health and social services. This healthcare and social service use, and quality of care transition over 180-d	ccessing important healthcare or program – a unique case rge plans, address their specific s study will examine health, ays after hospital discharge.
48 49 50 51 52 53 54 55 56	The care that you will receive in the hospital will not be changed if you de study. All research interventions and activities will be in addition to usual support during your hospital stay from care transition facilitators and/or so will also receive counselling from their care team and will be provided wir summary and/or prescription as needed.	ecide to participate in this care. Usual care consists of ocial workers. All participants th a written discharge
57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guid	delines.xhtml

CLINICAL TRIALS ONTARIO

661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

WHY IS THIS STUDY BEING DONE?

The purpose of this study is to examine if the Navigator program improves post-hospital outcomes for individuals experiencing homelessness. Findings from this research will be used to design new programs to improve care and post-hospital outcomes for individuals experiencing homelessness.

WHAT OTHER CHOICES ARE THERE?

You do not need to participate in this study to receive usual care from your care team, care transition facilitators, and/or social workers. However, please note that access to the Navigator program is limited to only those that participate in this study and are assigned to the Navigator program group.

HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?

It is anticipated that about 640 people will take part in this study, with 320 participants receiving the Navigator program and 320 receiving usual care.

This study should take 2 years to complete, and the results should be known in about 2.5 years.

WHAT WILL HAPPEN DURING THIS STUDY?

This is a randomized, controlled, and unblinded study. Randomized means you will be put into a group by chance, like flipping a coin. A computer program will place you into one of two study groups after the baseline interview. Your answers to the baseline interview will NOT determine which group you are placed in and the interviewer is NOT able to decide or influence which group you are placed in. You will have an equal 1 in 2 chance of being placed in one of two study groups. Group 1 includes those receiving the Navigator program and Group 2 includes those receiving usual care. This study is controlled because it includes a comparison group (Group 2), which is the usual care group that will receive the current standard of care. Unblinded means that you and your care team will know to which group you have been assigned.

WHAT IS THE STUDY INTERVENTION?

Participants in Group 1 will be assigned to a Homeless Outreach Counsellor. Participants in Group 2 will not be assigned to a Homeless Outreach Counsellor. The Homeless Outreach Counsellor will meet participants in the hospital and work with them for up to 90-days post-discharge. Services from the Homeless Outreach Counsellors will depend on the specific needs of the participants. The broad goals of the Navigator program are to link participants with resources in the community, support participants with their post-discharge plans, and help them meet their specific needs.

WHAT ARE THE STUDY PROCEDURES?

Interviews

If you consent to participate in the study, you will be asked to do a total of 2 interviews: one after you have enrolled in the study and another 30-days after your hospital discharge. The interviews will take approximately 30-45 minutes to complete. During the interviews, we will ask you a series of questions. We will collect basic information about you, your healthcare use, social service use, health status, medication adherence, care transition, and basic needs. You can skip questions that you do not wish to answer.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
10
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
30
20
39
40 41
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

60

CLINICAL TRIALS ONTARIO 661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

Trained research assistants will be conducting the interviews. The baseline interview may take place over the phone or in-person during your current hospitalization. The 30-day interview may take place over the phone or in-person at a location that is convenient for you.

We will ask you to provide contact information so we can reach you after your hospital discharge regarding the 30-day interview. This contact information may include your phone number and e-mail. We will also ask you to provide contact information for your friends, family members, or other agency contacts.

We will ask you to contact the research team 2-3 weeks after you are discharged from the hospital to schedule your 30-day interview.

Collecting Health-Related Data for research use

If you agree to participate in this study, the study staff will collect the following information from your medical records at Unity Health Toronto (St. Michael's Hospital): basic information about you and information about your current hospitalization. With your permission, we will also contact your primary care provider and other healthcare providers about your appointments after hospital discharge.

For participants in the Navigator program group, we will also collect information from your Homeless Outreach Counsellor about the number and nature of interactions that your Homeless Outreach Counsellor have with you, healthcare providers, and social services.

ICES DATA LINKAGE

We also ask for your permission to securely send your study data to ICES to be linked to information collected about your healthcare service use in Ontario. We will only be looking at what kinds of healthcare services you use and how often you use these services prior to enrollment in the study and after you have been discharged from the hospital . This will be done by linking your study data using your name, date of birth, and Ontario health card number to databases held at ICES. ICES is an independent and non-profit organization, whose core purpose is to conduct research that contributes to the effectiveness, quality, equity, and efficiency of healthcare and health services in Ontario. The ICES databases store information about physicians, hospitals, home care services, and medications that are paid for by the Ontario Health Insurance Plan (OHIP). This additional information will help us understand and measure the impact of the Navigator program on healthcare service use.

HOW LONG WILL PARTICIPANTS BE IN THE STUDY?

The study intervention will last throughout your hospital stay and for about 90 days after hospital discharge.

CAN PARTICIPANTS CHOOSE TO LEAVE THE STUDY?

Your participation in this study is completely voluntary. If you choose not to participate, there will be no impact to the medical care received, employment at, or other relationship with Unity Health now or in the future for you and your family.

	CLINICAL
	FRIALS
9	ONTARIO

661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

You can choose to end your participation in this research (called withdrawal) at any time without having to provide a reason. If you choose to withdraw from the study, you are encouraged to contact the study doctor or study staff. The study staff may ask you if you would like to re-join the study from time to time, but the decision is yours. You are not obligated to re-join the study.

If you withdraw from the study, no more data about you will be collected. The information you have provided us up until the time that you leave the study will still be kept for research purposes, unless you give us specific instructions to discard your data.

CAN PARTICIPATION IN THIS STUDY END EARLY?

The study doctor may stop your participation in the study early, and without your consent, for reasons such as:

- If continuation in the study appears to be harmful to you
- If it is discovered that you do not meet the eligibility requirements

If you are removed from this study, the study doctor will discuss the reasons with you.

WHAT ARE THE RISKS OR HARMS OF PARTICIPATING IN THIS STUDY?

Some of the interview questions may seem personal and may make you feel uncomfortable or may upset you. If this happens, you do not need to answer any question that you do not wish to, and you can let the interviewer know if you would like to take a break or stop the interview. If you would like to talk to the study staff, someone from your care team, or someone outside of St. Michael's Hospital for support after the interview, please let us know and we will help you to do that.

WHAT ARE THE BENEFITS OF PARTICIPATING IN THIS STUDY?

Participants receiving the Navigator program may benefit from the case management service.

HOW WILL PARTICIPANT INFORMATION BE KEPT CONFIDENTIAL?

This section describes how your personally identifying information and study data will be accessed, disclosed, and stored during this study. Personally identifying information is any information that could be used to identify you and includes your name and date of birth. Study data is information that is generated by and/or collected for a study that has been stripped of personally identifying information.

All persons involved in study will make every effort to keep your personally identifying information private and confidential in accordance with all applicable privacy legislation, including the Personal Health Information Protection Act (PHIPA) of Ontario. This information will only be used to get in touch with you and access your health records with your consent. All study data collected for research purposes will be labelled with a unique study identification number instead of your personally identifying information. The Survey Research Unit at St. Michael's Hospital is in control of the key that links your study identification number to you personally and will keep it stored separately from the study data. No personally identifying information will be allowed off site in any form, unless required by law. Other than the study team or groups described in this section, no persons will have access to your personally identifiable information without your consent, unless required by law. In addition to the

CLINICAL TRIALS ONTARIO 661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

study personnel, other employees of Unity Health Toronto may have access to your personally identifying information so that they can carry out regulatory or institutionally required duties.

Accessing and Collecting Information from Your Unity Health Toronto Medical Record

By signing this form, you are authorizing access to your medical records by the study team. The study team will also collect information from your medical record. The information that will be collected is described in the Study Procedures section. The study team will use this information to conduct the study.

You are also authorizing access to your medical records by representatives of the Unity Health Toronto Research Ethics Board. Such access will only be used to verify the authenticity and accuracy of the information collected for the study, without violating your confidentiality, to the extent permitted by applicable laws and regulations.

Accessing and Collecting Information from Providers

By signing this form, you are giving us permission to contact your healthcare providers. These providers may ask you to give separate consent to allow them to release your medical information to us. The information that will be collected from other institutions or providers is described in the Study Procedures section. The study personnel will use this information to conduct the study.

Linking to ICES

Personally identifying information will be securely transferred from St. Michael's Hospital by the study investigators to ICES so the required links can be made to collect study data. The information that will be sent is described in the Study Procedures section.

Use of email/Texting for research

There are common risks of using email and/or texting to communicate:

- Information travels electronically and is not secure in the way a phone call or regular mail would be.
- If someone sees these emails and/or texts they may know that you are a participant in this study or see any health information included in the email and/or text.
- Emails and/or texts may be read or saved by your internet or phone provider (i.e. Rogers, your workplace, and "free internet" providers).
- Copies of an email and/or text may continue to exist, even after efforts to delete the email and/or text have been made.
- There is always a chance with any unencrypted email and/or text, however remote, that it could be intercepted or manipulated.

Do not use email and/or text messaging for medical emergencies. If you require immediate help, call your clinic or care provider, or seek emergency services.

Personally identifying information and study data storage

All data used in this study will be securely stored. At each interview, responses will be collected electronically using SNAP Professional Software. This platform has been reviewed and approved for use by St. Michael's Hospital. All electronic data will be kept on a secure server in an unreadable format for anyone outside of the study. Study data may be transferred outside of Unity Health Toronto and may be

CLINICAL TRIALS ONTARIO

661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

shared with others for purposes related to the conduct of this research study. Representatives of Clinical Trials Ontario, a not-for-profit organization, may see study data that is sent to the Unity Health Toronto Research Ethics Board.

Personally identifying information Retention

Personally identifying information collected for research purposes will be kept by the Principal Investigator and Unity Health Toronto for as long as required by Unity Health Toronto policy (currently 7 years after the study ends), at which point any documents with personally identifying information will be destroyed.

We may wish to contact you in the next 3 years regarding additional research related to this study. You are under no obligation to participate in additional research. At the end of this consent form you can let us know if you give permission for us to contact you again. If you do not want to be contacted about future research, the list connecting your personal information (such as your name and address) to your unique study identification number will be destroyed upon completion of analysis. If you do consent to be contacted about future research, we will keep this information until the end of the 3-year period. All other electronic files will be deleted, and consent forms will be destroyed 7 years after the end of the study.

STUDY DATA RETENTION

As a reminder, study data is information that is generated by or collected for a study that has been stripped of personally identifying information. Study data may be kept indefinitely and may be used for other research or analyses by the investigators. However, the results of any research from this study will include information from many people grouped together so that no one person can be identified. No records of personal information that could be linked to you will ever be reported. The Principal Investigator will protect your records and keep all your information confidential to the greatest extent possible by law.

WILL FAMILY DOCTORS/HEALTH CARE PROVIDERS KNOW WHO IS PARTICIPATING IN THIS STUDY?

On the signature page of this consent form, you will be asked to consent to allow the study team to contact your family doctor and healthcare providers about your appointments after your hospitalization.

WILL INFORMATION ABOUT THIS STUDY BE AVAILABLE ONLINE?

A description of this clinical trial will be available on <u>http://www.ClinicalTrials.gov</u>. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time. You may also contact the Principal Investigator after the study is completed to access and discuss results.

WHAT IS THE COST TO PARTICIPANTS?

Participation in this study will not involve any direct additional costs to you. If you need to travel to and from the 30-day interview, you will also be reimbursed for the cost of round-trip public transportation fare.

59

7

8

9

20

21

22

23

24 25 26

27

28

29

30 31

32 33 34

35

36

37

38 39

40 41

42

BMJ Open

1		
2	CLINICAL	
3	TRIALS	
4	ONTARIO	
5		

661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

ARE STUDY PARTICIPANTS PAID TO BE IN THIS STUDY?

If you agree to participate in the study, you will be provided with honorariums after each interview to compensate you for your time. After the baseline interview, you will be provided with a \$20 Tim Horton's gift card or another type of gift card such as a Presto gift card or a grocery gift card for the 10 11 same amount, if requested. After the 30-day interview, you will be provided with \$40 by cash, e-12 transfer, or cheque. Honorariums after each completed interview will be provided to you whether or not 13 you complete the entire study. If you contact the research team 2-3 weeks after you are discharged from 14 the hospital to schedule your 30-day interview, you will be provided with an additional \$10, and will 15 receive this at the 30-day interview, for a total of \$50. If you do not contact the research team to 16 schedule the interview, we will contact you and you will not receive the additional \$10. All participants 17 who complete the 30-day interview will receive the same \$40 compensation for their time. 18 19

WHAT ARE THE RIGHTS OF PARTICIPANTS IN A RESEARCH STUDY?

You will be told, in a timely manner, about new information that may be relevant to your willingness to stay in this study. You have the right to be informed of the results of this study once the entire study is complete.

Your rights to privacy are legally protected by federal and provincial laws that require safeguards to ensure that your privacy is respected. By signing this form, you do not give up any of your legal rights against the study doctor or involved institutions for compensation, nor does this form relieve the study doctor or their agents of their legal and professional responsibilities.

You will be given a copy of this signed and dated consent form prior to participating in this study.

WHOM DO PARTICIPANTS CONTACT FOR QUESTIONS?

If at any time during the study you have questions about the study or the research activities, you should contact the Principal Investigator, Dr. Stephen Hwang, at 416-864-5991(M-F, 9 AM-5PM), or contact the Research Coordinator, Rebecca Brown, at 416-864-6060 ext. 77492 (M-F, 9 AM-5PM).

If you have any questions regarding your rights as a research participant, you may contact the Unity Health Toronto Research Ethics Board Office at 416-864-6060 ext. 42557 during business hours (9:00am to 5:00pm).

CLINICAL TRIALS ONTARIO

1

2

3

661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

Signature Pages: Documentation of Informed Consent <u>EFFECT OF A NAVIGATOR PROGRAM ON POST-HOSPITAL OUTCOMES FOR HOMELESS ADULTS: A</u> <u>PRAGMATIC RANDOMIZED CONTROLLED TRIAL</u>

Participant Statement of Consent

By signing this consent form, I acknowledge that:

- This research study has been explained to me, and my questions have been answered to my satisfaction.
- I have been given sufficient time to read and understand the information in this consent form.
- I have been informed of the alternatives to participation in this study.
- I know that I have the right not to participate and the right to withdraw from this study without affecting the medical care received, employment at, or other relationship with Unity Health now or in the future for me or my family.
- The potential risks and benefits (if any) of participating in this research study have been explained to me.
- I have been told that I have not waived my legal rights nor released the investigator or involved institutions from their legal and professional responsibilities.
- I know that I may ask, now or in the future, any questions I have about this study.
- I have been told that information about me and my participation in this study will be kept confidential and that no personally identifying information will be disclosed without my permission unless required by law.
- I will be given a signed and dated copy of this consent form.

I consent to participate in this study.

Participant Name (Print)	Participant Signature	Date	Time

I have explained to the above-named participant the nature and purpose, the potential benefits, and possible risks of participation in this research study. All questions that have been raised about this study have been answered.

Name of Person Obtaining Consent (Print) Position/Title of Person Obtaining Consent (Print) Signature of Person Obtaining Consent Time

Date
Consent for Telephone Completion (Research Staff Only) I have explained to the participant the nature, purpose, potential benefits, and possible risks asses with participation in this research database. I confirm that the information in the letter of inform and any other written information was accurately explained to, and apparently understood by, the participant. I have answered all questions that have been raised. I will send a copy of the letter of information to the participant for his/her records. Name of Person Position/Title of Person Obtaining Consent (Print) Consent signed for: Name of Participant Name of Information sent by: Name of Participant Name of Participant Date	LINICAL RIALS NTARIO				661 Univer MaRS Cen Toronto, O M5G 1M1 www.ctont	sity Avenue tre, West Te ntario Canada ario.ca	e, Suite 4 ower
I have explained to the participant the nature, purpose, potential benefits, and possible risks asso with participation in this research database. I confirm that the information in the letter of inform and any other written information was accurately explained to, and apparently understood by, the participant. I have answered all questions that have been raised. I will send a copy of the letter of information to the participant for his/her records. <u>Name of Person</u> <u>Obtaining Consent</u> (Print) <u>Position/Title of Person Obtaining Consent (Print) <u>Person Obtaining</u> Consent Consent signed for: <u>Name of Participant</u> <u>Date</u> Letter of Information sent by: <u>Name of Participant</u> <u>Date</u></u>	Consent for Telephone Compl	etion (Research Staff	Only)				
I will send a copy of the letter of information to the participant for his/her records.	have explained to the participa with participation in this researc nd any other written informatic articipant. I have answered all	ant the nature, purpose, j th database. I confirm th on was accurately expla questions that have bee	potential bo nat the info ined to, and n raised.	enefits, rmatior d appare	and possib in the lette ently under	le risks as er of infor stood by,	ssociate mation the
Name of Person Obtaining Consent (Print) Position/Title of Person Obtaining Consent Signature of Person Obtaining Consent Date Consent signed for: Image: Ima	will send a copy of the letter of	f information to the par	ticipant for	his/her	records.		
Consent signed for: Image: Online	Name of Person Obtaining Consent (Print)	Position/Title of Person Obtaining Consent (Print)	Sign Person Co	ature of Obtain	f ing	Date	Tii
Name of Participant Date Letter of Information sent by: on Name of Participant Date	Consent signed for:			on			
Letter of Information sent by: Name of Participant Date		Name of Partici	oant			Date	
Letter of Information sent by: Name of Participant Date							
Name of Participant Date	etter of Information sent by:			on			

CLINICAL TRIALS ONTARIO	IICAL661 University Aver MaRS Centre, West Toronto, OntarioLSToronto, OntarioM5G 1M1 Canada www.ctontario.ca			sity Avenue, Suite 460 rre, West Tower ntario Canada ario.ca
CONSENT TO CONTACT HE I consent to the study staff on my appointments for the pu	EALTHCARE PROVI contacting my prima urpose of this study.	DERS ary care provider and	l other healthcare	providers regardin
		\Box Yes	(initials)	□ Declined
CONSENT TO REVIEW MEI	DICAL RECORDS AT	ST. MICHAEL'S HO	SPITAL	
I consent to the study staff r and hospitalization history f	reviewing my medic for the purpose of th	al records at St. Mich	hael's Hospital re	egarding my medic
	6	□ Yes	(initials)	□ Declined
CONSENT TO THE RELEAS I consent to the study staff of to be contacted if needed), of purpose of conducting the 3	E OF INFORMATION contacting the indivi- organizations, and a 30-day follow-up int	N BY CONTACT PERS iduals I have listed as gencies that I use wh rerview. I agree to all	SONS s alternate contaction in attempting to low the study staf	ts (who have agree contact me for the ff to link my name,
CONSENT TO THE RELEAS I consent to the study staff of to be contacted if needed), of purpose of conducting the 3 gender, date of birth, and he these people to release infor study staff.	E OF INFORMATION contacting the indivi- organizations, and a 30-day follow-up int ealth card number to rmation regarding m	N BY CONTACT PERS iduals I have listed as gencies that I use wh rerview. I agree to all o obtain information ny up-to-date mailing	SONS is alternate contact one attempting to ow the study staf from these agenc g address and pho	ets (who have agree contact me for the ff to link my name, ies. I authorize one number to the Declined
CONSENT TO THE RELEAS I consent to the study staff of to be contacted if needed), of purpose of conducting the 3 gender, date of birth, and he these people to release infor study staff.	E OF INFORMATION contacting the indivi- organizations, and a 30-day follow-up int ealth card number to rmation regarding m	N BY CONTACT PERS iduals I have listed as gencies that I use where erview. I agree to all o obtain information by up-to-date mailing	SONS s alternate contaction attempting to low the study staff from these agence g address and pho	ets (who have agree contact me for the ff to link my name, ies. I authorize one number to the Declined
CONSENT TO THE RELEAS I consent to the study staff of to be contacted if needed), of purpose of conducting the 3 gender, date of birth, and he these people to release infor study staff. CONSENT TO THE RELEAS COUNSELLORS I consent to the study staff a this study.	E OF INFORMATION contacting the indivi- organizations, and a 30-day follow-up int ealth card number to rmation regarding m	N BY CONTACT PERS iduals I have listed as gencies that I use where erview. I agree to all o obtain information by up-to-date mailing U Yes	SONS s alternate contaction ow the study staff from these agenc g address and pho (initials) BY THE HOMELI ellor case notes f	ets (who have agree contact me for the ff to link my name, ies. I authorize one number to the Declined ESS OUTREACH
CONSENT TO THE RELEAS I consent to the study staff of to be contacted if needed), of purpose of conducting the 3 gender, date of birth, and he these people to release infor study staff. CONSENT TO THE RELEAS COUNSELLORS I consent to the study staff a this study.	E OF INFORMATION contacting the indivi- organizations, and a 30-day follow-up int ealth card number to rmation regarding m E OF HEALTH RECO accessing my Home	N BY CONTACT PERS iduals I have listed as gencies that I use wh erview. I agree to all o obtain information is ny up-to-date mailing U Yes ORD INFORMATION less Outreach Couns U Yes	SONS as alternate contact an attempting to ow the study stafform these agence g address and pho (initials) BY THE HOMELI ellor case notes f (initials)	ets (who have agree contact me for the ff to link my name, ies. I authorize one number to the Declined ESS OUTREACH for the purpose of Declined
CONSENT TO THE RELEAS I consent to the study staff of to be contacted if needed), of purpose of conducting the 3 gender, date of birth, and he these people to release infor study staff.	E OF INFORMATION contacting the indivi- organizations, and a 30-day follow-up int ealth card number to rmation regarding m E OF HEALTH RECO accessing my Home	N BY CONTACT PERS iduals I have listed as gencies that I use whe erview. I agree to all o obtain information is ny up-to-date mailing U Yes DRD INFORMATION less Outreach Couns U Yes	SONS a salternate contact ien attempting to ow the study stafform these agence g address and pho (initials) BY THE HOMELI ellor case notes f	ets (who have agree contact me for the ff to link my name, ies. I authorize one number to the Declined ESS OUTREACH For the purpose of Declined
CONSENT TO THE RELEAS I consent to the study staff of to be contacted if needed), of purpose of conducting the 3 gender, date of birth, and he these people to release infor study staff. CONSENT TO THE RELEAS COUNSELLORS I consent to the study staff a this study. CONSENT TO THE RELEAS I consent to the study staff a Ministry of Health files to of and for the next year.	E OF INFORMATION contacting the indivi- organizations, and a 30-day follow-up int ealth card number to rmation regarding m E OF HEALTH RECO accessing my Home E OF HEALTHCARE linking my provinci obtain information a	N BY CONTACT PERS iduals I have listed as gencies that I use whe erview. I agree to all o obtain information is ny up-to-date mailing U Yes ORD INFORMATION less Outreach Couns U Yes USE INFORMATION al health card number bout my use of healt	SONS a alternate contact a alternate contact a ow the study staff from these agence address and pho (initials) BY THE HOMELI ellor case notes f (initials) FOR ICES DATA er, my name, sex, hcare services for	ets (who have agree contact me for the ff to link my name, ies. I authorize one number to the Declined ESS OUTREACH for the purpose of Declined

CLINICAL
TRIALS
ONTARIO

661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca

Consent to be Contacted in the Future for Research Purposes

We would also like to ask that you consider providing consent to be contacted about future research studies. The information that you should consider before agreeing to this is outlined below.

The study staff may wish to contact you in the next 3 years regarding additional research related to this study and the Navigator program. Study staff may contact you through phone or e-mail. Your contact information will be stored in the Master Linking Log that will be kept separately from the study data by the Survey Research Unit at St. Michael's Hospital. This data will be stored on a secure server in a password protected file. Only members of the study staff who are not connected to any part of your care will have access to your contact information.

You are not obligated to participate in any research studies that you are contacted about. If you no longer want to be contacted about future research studies, please contact the research coordinator, Rebecca Brown, at 416-864-6060 ext. 77492 (M-F, 9 AM-5PM).

STATEMENT OF CONSENT TO BE CONTACTED IN THE FUTURE FOR RESEARCH PURPOSES

I agree to be contacted by email.
Email address:
*Please note that email is not secure. Emails can be intercepted, viewed, changed, or
saved by others
I agree to be contacted by telephone/text.
Telephone Number:
I agree that the study staff can leave a voicemail or message if I do not answer the
telephone.

I have read the above information, and I agree to be contacted for future research as indicated above.

Participant Name (Print)

Participant Signature

Date

CLINICAL TRIALS ONTARIO		661 University A MaRS Centre, W Toronto, Ontario M5G 1M1 Canad www.ctontario.ca	venue, Suite 4 est Tower a
If participant is not able to read inde	ependently for any reason:		
Declaration	<u>of Assistance – Witness to Cons</u>	<u>ent Process</u>	
Study Participant's Name (Print):			
ASSISTANCE DECLARATION A I have provided assistance during the obtaining consent by (please check o □ Acting as a witness to the com □ Assisting in delivery of conser and responses □ Other: I attest that the information was accur participate in the research study.	AND SIGNATURE: e consent discussion between the pone): sent discussion nt discussion (reading/oral), inclu	potential participant ding communication ant has freely given	and the per n of question consent to
Name of Person Assisting	Signature of Person	Date	Time
Consent (Print)	Assisting Consent		
Contact Information of Person Ass	sisting Consent:	2	

CLINICAL TRIALS ONTARIO			661 University A MaRS Centre, W Toronto, Ontario M5G 1M1 Canad www.ctontario.ca	venue, Suite est Tower a
If participant has lin	nited proficiency	in English:		
	Decla	aration of Assistance – Interpre	<u>eter</u>	
Study Participant's N	Name (Print):			
INTERPRETER D I am competent in th	ECLARATION le English langua	AND SIGNATURE: age and in the preferred language (name of language)	e of the potential part	cicipant:
I am not involved in personally identifyin and provided a sight obtaining consent.	the research stud ig information of translation of the	ly or related to the participant. I the participant. I have faithfully e written informed consent form	agree to keep confid interpreted the cons as directed by the st	ential all eent discus udy staff
Name of Interpre	reter (Print)	Signature of Interpreter	Date	Tir

2	
3	
4	
5	
6	
0	
/	
8	
9	
1	0
1	1
1	2
1	- 2
1	л Л
1	4 7
1	5
1	6
1	7
1	8
1	9
2	0
2	1
2	י ר
2	2 2
2	3
2	4
2	5
2	6
2	7
2	8
2	9
2	ñ
נ ר	1
3	1
3	2
3	3
3	4
3	5
3	6
3	7
2	, o
נ ר	0
3	9
4	0
4	1
4	2
4	3
4	4
4	5
4	6
т Л	7
4	/
4	8
4	9
5	0
5	1
5	2
5	3
5	⊿
כ ב	+
2	כ ר
5	6
5	7
5	8

60

1

Online Supplemental	File 2: Adjudication	Rules for Primary Outcome
----------------------------	----------------------	----------------------------------

Α	В	С	D	Ε
Patient 30-day	Primary Care	Adjudication of	ICES	Final Adjudication
Interview	Office Report ¹	A and B	Administrative	(Yes if C=Yes or
Self-Report			Data	D=Yes)
Yes	Yes	Yes	Yes	Yes
Yes	Yes	Yes	No	Yes
Yes	Yes	Yes	n.d.	Yes
Yes	No	No	Yes	Yes
Yes	No	No	No	No
Yes	No	No	n.d.	No
Yes	n.d.	Yes	Yes	Yes
Yes	n.d.	Yes	No	Yes
Yes	n.d.	Yes	n.d.	Yes
No	Yes	Yes	Yes	Yes
No	Yes	Yes	No	Yes
No	Yes	Yes	n.d.	Yes
No	No	No	Yes	Yes
No	No	No	No	No
No	No	No	n.d.	No
No	n.d.	No	Yes	Yes
No	n.d.	No	No	No
No	n.d.	No	n.d.	No
n.d.	Yes	Yes	Yes	Yes
n.d.	Yes	Yes	No	Yes
n.d.	Yes	Yes	n.d.	Yes
n.d.	No	No	Yes	Yes
n.d.	No	No	No	No
n.d.	No	No	n.d.	No
n.d.	n.d.	No	Yes	Yes
n.d.	n.d.	No	No	No
n.d.	n.d.	No	n.d.	No

n.d. = no data.

¹The primary care provider (PCP) office will be contacted under any of the following circumstances: (1) participant reports PCP visit at the 30-day interview, (2) participant reports no PCP visit at the 30-day interview AND a PCP is identified at the baseline interview or 30-day interview, or (3) participant misses the 30-day interview AND a PCP is identified at the baseline interview.

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
20	
28	
29	
30	
31	
32	
33	
34	
35	
36	
3/	
38	
39 40	
40 41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52 52	
55 54	
55	
56	
57	
58	
59	
60	

Instrument	Description			
EQ-5D-3L and VAS	The EQ-5D-3L is a generic measure of health-related quality of life that has been widely used among the homeless population. The EQ-5D-3L includes five three-level items concerning mobility, self-care, usual activities, pain/discomfort, and anxiety/depression that are weighted to produce a single utility score between 0 and 1.			
	The Visual Analogue Scale (VAS) of the EQ-5D-3L will also be included, which will allow participants to rate their overall health, mental health, and physical health from 0 to 100.			
	References:			
	 Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., & Busschbach, J. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Quality of life research</i>, 22(7), 1717-1727. Stergiopoulos, V., Hwang, S. W., Gozdzik, A., Nisenbaum, R., Latimer, E., Rabouin, D., & At Home/Chez Soi Investigators. (2015). Effect of scattered-site housing using rent supplements and intensive case management on housing stability among homeless adults with mental illness: a randomized trial. <i>JAMA</i>, 313(9), 905-915. 			
MMAS-8	The MMAS-8 is a validated self-reported measure for medication-taking behavior that has been used among disadvantaged patients and those with chronic illnesses.			
	The MMAS-8 consists of eight items, the first seven of which are yes/no questions, and the last of which is a five-point Likert-scale rating. Each "no" response is rated as "1" and each "yes" is rated as "0" except for item 5, in which each "yes" is rated as "1" and each "no" is rated as "0". For item 8, if a patient chooses response "0", the score is "1" and if they choose response "4", the score is "0". Responses "1, 2, 3" are respectively rated as "0.25, 0.75, 0.75". Total MMAS-8 scores can range from 0 to 8 and are categorized into three levels of adherence: high adherence (score = 8), medium adherence (score of 6 to 8), and low adherence (score < 6).			
	References:			
	 Moon, S. J., Lee, W. Y., Hwang, J. S., Hong, Y. P., & Morisky, D. E. (2017). Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. <i>PloS one</i>, <i>12</i>(11), e0187139. Feehan, M., Morrison, M. A., Tak, C., Morisky, D. E., DeAngelis, M. M., & Munger, M. A. (2017). Factors predicting self-reported medication low adherence in a large sample of adults in the US general population: a cross sectional study. <i>BMJ open</i>, <i>7</i>(6), e014435. 			

CTM-3	 The most widely used measure of care transition quality is the Care Transition Measure (CTM). The CTM-3 is an abbreviated version of the original CTM-which measures the extent to which the healthcare team accomplished essent care processes in preparing the patient for discharge and participating in post hospital self-care activities. The CTM-3 consists of three items with a four-point scale with responses ran from "Strongly Disagree" (1) to "Strongly Agree" (4) to the following questiont of the hospital stay, staff took my preferences into account in deciding what my healthcare needs would be when I left. When I left the hospital, I had a good understanding of the things I w responsible for in managing my health. When I left the hospital, I clearly understood the purpose for taking of my medications Items are scored by summing the responses and then linear transforming to a range. References: Parry, C., Mahoney, E., Chalmers, S. A., & Coleman, E. A. (2008). Assessing the quality of transitional care: further applications of the transitions measure. <i>Medical care</i>, 317-322.
RAND Course of Homelessness Scale	 Assessing the quality of transitional care: further applications of the transitions measure. <i>Medical care</i>, 317-322. Coleman, E. A., Smith, J. D., Frank, J. C., Eilertsen, T. B., Thiare, J Kramer, A. M. (2002). Development and testing of a measure design assess the quality of care transitions. <i>International journal of integra care</i>, <i>2</i>. Developed specifically for homeless populations, the RAND scale is a five-i index of self-reported difficulty in meeting the following subsistence needs of the past 30 days: frequency of difficulty in finding shelter, enough to eat, close a place to wash, and a place to use the bathroom. Possible responses to each are never (1), rarely (2), sometimes (3), or usually (4) with total scores betwee 20. Reference:
	 Reference: 1. Gelberg, L., Gallagher, T. C., Andersen, R. M., & Koegel, P. (1997) Competing priorities as a barrier to medical care among homeless ad Los Angeles. <i>American journal of public health</i> 87(2), 217-220

BMJ Open



46



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative inf	ormatio	n	
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	23
Roles and	5a	Names, affiliations, and roles of protocol contributors	1 and 23
responsibilities	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	23
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A

1 2	Introduction			
3 4 5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5-7
6 7		6b	Explanation for choice of comparators	10
8 9	Objectives	7	Specific objectives or hypotheses	7
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7-9
14 15	Methods: Particip	ants, int	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7-8
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8
22 23 24 25	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9-11
26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	N/A
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
34 35 36 37 38 39 40	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12-14
42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 49	of 51
---------	-------

1 2	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8-9		
3 4 5 6	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	15		
7 8	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8-9		
9 10	Methods: Assignme	nt of in	iterventions (for controlled trials)			
11 12	Allocation:					
13 14 15 16 17 18	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9		
19 20 21 22	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9		
23 24 25 26	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9		
20 27 28 29	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	15		
30 31 32		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	15		
33 34 35	Methods: Data collection, management, and analysis					
36 37 38 39 40 41 42 43 44	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	12-14		
46						

1 2 3 4 5 6 7		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9		
	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	21-22		
8 9 10	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	15-20		
11 12		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	15-20		
13 14 15 16		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	17		
17 18	Methods: Monitoring					
19 20 21 22 23 24	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A		
25 26 27		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A		
28 29 30 31 32 33	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	N/A		
	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A		
34 35 26	Ethics and dissemin	nation				
37 38 39 40	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	20		
41 42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml			

Page 51 of 51

BMJ Open

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	21
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	Appendix
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	21-22
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	23
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	21-22
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	21-22
	31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	21-22
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "<u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u>" license.

 For peer review only